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The persistence of latent viral reservoirs, that are insensitive to antiretroviral therapy 
(ART), remains the greatest barrier to HIV-1 eradication. The role that viral factors play 
in HIV-1 latency establishment and maintenance is poorly understood, and 
characterisation of these factors is imperative for the development of curative 
strategies or interventions that could lead to HIV-1 remission in infected individuals. 
Subtype level genotypic variation within regulatory elements of the HIV-1 promoter, 
the long terminal repeat (LTR), has been shown to influence latency establishment in 
in vitro models. We investigated the influence of inter-participant subtype C LTR 
genotypic variation on the establishment of latency in a dual reporter HIV-1 plasmid 
model and evaluated potential correlates of this latency potential. 
 
Long terminal repeats from 11 ART-naïve, acutely subtype-C infected women in the 
CAPRISA 004 cohort from Durban, South Africa were cloned into an HIV-1-expressing 
vector (pRGH) used to generate pseudovirions following HEK293T transfection. 
Pseudoviruses harboured a gag-eGFP gene under the control of the participant LTR, 
allowing measurement of active replication, and an mCherry gene under the control of 
a constitutive CMV promoter allowing measurement of viral integration. Latency 
potential was expressed as the ratio of mCherry only (latent) to eGFP and mCherry 
(active replication), as measured by flow cytometry after infection of Jurkat E6-1 and 
CEM.NK
R
 CCR5+ cell lines before and after T cell activation with PMA/Ionomycin. A 
panel of LTRs cloned into a pGL4.10 luciferase expression vector were used to 
measure basal LTR expression and Tat-induced LTR expression. 
 
All LTR sequences were classified as subtype C, with an average inter-participant 
pairwise DNA distance of 7.6%. The median basal LTR activity was approximately two 
times higher than that of the BaL isolate (interquartile range: 1.38-2.14), and Tat-
induced activity approximately nine times higher than that of BaL (interquartile range: 
6.16-10.33). We observed consistently greater proportions of latently infected cells 
than actively infected cells. In Jurkat E6-1 cells, the median latent:active infection ratio 
was 1.97 (range 0.86-2.83; three experiments). Latency was reversible in a proportion 
of cells as the median latent:active infection ratio decreased to 0.55 (range 0.46-0.78). 
 xi 
The latent:active ratio was unchanged, post-stimulation, in CEM.NK
R 
CCR5+ cells and 
was therefore found not to be a suitable cell-line for the model. Latency potential did 
not correlate with basal or Tat-induced activity (Spearman correlation tests, basal 
p=0.25, r=-0.38, Tat-induced p=0.42, r=-0.27). The DNA distance in characterised 
functional sites from consensus did not correlate with latency potential (Spearman 
correlation test p=0.67, r=0.14). 
 
Our data suggest that HIV-1 LTRs have intrinsic properties which influence latency 
potential and the proportion of latently infected cells early post-infection. However, 
since differences were independent of basal and Tat-induced LTR activity, other 
factors such as regulatory element interaction and the efficiency of recruitment of 
molecules responsible for establishing latency, such as histone modifiers, may play a 
role. 
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The Human Immunodeficiency Virus type 1 (HIV-1) is the pathogen responsible for 
Acquired Immunodeficiency Syndrome (AIDS)(1, 2). To date, HIV-1/AIDS has been 
responsible for up to 35 million deaths worldwide. In 2016, approximately 36.7 million 
people were living with HIV-1, 1.8 million new infections were recorded, and 1 million 
people died from AIDS-related illnesses. South Africa remains one of the countries 
with the highest HIV-1 prevalence with 7.1 million people (19% of global infections) 
living with HIV-1 at the end of 2016(3). 
 
In many areas of the world, the number of new HIV-1 infections are declining as a 
result of increasing coverage of antiretroviral therapy (ART), as patients with 
suppressed viral loads are less likely to transmit the virus(4). However in 2016, only 
56% of infected individuals in South Africa had access to treatment(3). Antiretrovirals 
(ARVs) are also used in pre-exposure prophylaxis (PrEP), however, there is as yet no 
evidence that this is contributing to controlling the epidemic. With ARVs used for both 
treatment and prevention, the emergence of drug resistance, which would render ART 
ineffective, is a concern(5). While ART can suppress viral loads to below detectable 
levels and prolong life, these drugs are unable to eradicate the virus from the body 
due to persistence of latent viral reservoirs and anatomical sanctuaries where drugs 
are unable to penetrate(6, 7). Furthermore, sustaining life-long treatment of large 
populations of infected individuals is challenging and economically unviable(8). 
Therefore, urgent efforts are needed to either improve the current treatment strategies 
or work towards development of an HIV-1 cure or state of remission (control in 
absence of therapy). 
 
HIV-1 latency allows the virus to remain within infected cells for many years unaffected 
by treatment and undetected by host immune responses. However, when ART is 
discontinued, viral replication is reinitiated, allowing the rapid re-emergence of 
viremia(9, 10). Most strategies aimed at eliminating the latent reservoir are geared 
towards reactivating latent viruses while patients are still on ART(11). Unfortunately, 
the factors that govern HIV-1 latency are still poorly understood, particularly the 
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contribution of the viral factors such as genotypic variability, which is the focus of this 
thesis. 
 
This literature review will cover aspects of the structure of the HIV-1 genome focussing 
on the organisation of the HIV-1 promoter element, the long terminal repeat (LTR), 
and cellular transcription factors that play a role in regulation of its function. 
Furthermore, the molecular mechanisms of viral latency establishment and 
maintenance will be described with particular attention given to those mechanisms 
that act directly on the LTR. Finally, the current models available for the study of viral 
latency and strategies to reverse latency will be described. 
 
1.2 Hope for an HIV-1 Cure 
 
A number of recent case studies(12–16) providing evidence of the possibility of a cure 
have driven a strong interest in HIV-1 cure research. Most noteworthy is the report of 
Timothy Ray Brown, the “Berlin patient” who is the only individual reported to be cured 
of HIV-1 infection(12). The Berlin patient was on ART when he developed myeloid 
leukaemia. After chemotherapy and irradiation therapy, he received a hematopoietic 
stem cell (HSC) transplant from a donor who was homozygous for a 32 base-pair 
deletion in the CCR5 gene, a gene encoding an essential co-receptor for HIV-1 
infection. These cells are therefore resistant to HIV-1 infection. This patient has been 
off therapy for approximately nine years and has shown no evidence of viral rebound. 
This is an example of a sterilizing cure where the virus was completely eradicated from 
the infected individual.  
 
In two similar cases, the “Boston patients”, the HSC transplant was likewise attempted, 
however the stem cell donors were heterozygous for the 32 base-pair deletion in the 
CCR5 gene and the patients remained on ART post-transplant in the hopes of 
preventing infection of donor cells(13). Disappointingly, only a delay in viral rebound 
was observed in both patients after ART was discontinued. It is possible that a subset 
of remaining latently infected cells were reactivated and were ultimately responsible 
for viral rebound. 
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Further evidence of the possibility of a cure is provided by the cases of the Mississippi 
baby and the Virological and Immunological Studies in Controllers after Treatment 
Interruption (VISCONTI) cohort where ART was initiated in infected individuals very 
early post-infection and was interrupted after 18 months and an average of three years 
respectively(14, 15). The Mississippi baby experienced remission but eventually 
succumbed to viral rebound. The majority of the men in the VISCONTI cohort did not 
experience viral rebound for at least ten years off therapy. 
 
In addition, two other cases have been reported where a French teenage girl and 
South African child have experienced remission for 12 and eight years respectively(17, 
18). Both individuals were infected at birth and treated within three months after birth 
and treated for six years and 40 weeks respectively. 
 
These incidences demonstrate the possibility of a functional cure where an infected 
individual may live disease-free without treatment, while still harbouring the virus. 
Additionally, they highlight the need to understand the dynamics of the inducible latent 
reservoir and to develop a strategy to purge it. 
 
1.3 HIV classification 
 
HIV is a lentivirus that is part of the larger retrovirus group. It can be classified into two 
types/lineages, namely HIV type 1 and 2 (HIV-1 and HIV-2) which are a result of 
separate zoonotic transmission events(19). HIV-1 is the dominant type, accounts for 
the vast majority of global infections, and is responsible for the AIDS pandemic. A 
small percentage of HIV-2 infections occur chiefly in West African regions, however 
this type is less pathogenic(20). 
 
HIV-1 is further classified based on origin and genotype. Firstly, HIV-1 is comprised of 
four groups that are assigned as follows: group M (major), which is responsible for 
over 95% of infections, group O (outlier), group N (non-M/non-O) and the most recently 
discovered group P(21–23). HIV-1 group M has diversified over time into 9 discrete 
subtypes: A, B, C, D, F, G, H, J and K. Subtype C, the dominant virus in South Africa, 
is reported to be responsible for the majority of infections globally, with subtypes A, B, 
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G and D contributing significantly (Figure 1.1)(24). In addition, HIV-1 group M has 
further diversified into 96 circulating recombinant forms (CRFs) (25). These CRFs are 
formed when recombination occurs between subtypes within an individual infected 
with two or more subtypes. These recombinants are subsequently passed on to other 
individuals(26). The recombinant forms AG and AE collectively contribute to 
approximately 13% of global infections. 
 
The HIV-1 M subtypes are differentially represented in terms of geographical location. 
Of importance, the dominant subtype C viruses are responsible for the majority of 
infections in the greater part of Southern Africa, India and Ethiopia. Subtype A is 
overrepresented in areas of Central Asia, Eastern Europe and Central and West 
Africa. In North and Latin America, Western Europe, and East Asia infections are 
predominantly caused by Subtype B viruses. Subtype D is mainly isolated in patients 
in Northern, Western and East Africa. Most Subtype G infections are located in certain 
regions of Western Africa. There is no evidence for geographical overrepresentation 
of subtypes, F, H, J and K(24). 
 
 
Figure 1.1 Global contribution of HIV-1 group M subtypes. The percentage of total infections 























1.3.1 HIV-1 subtype pathogenicity 
 
In addition to differences in genotype and geographic distribution, the different HIV-1 
group M subtypes display different degrees of pathogenicity. Of importance, Amornkul 
et al.(27) reported that subtype C infected individuals experience a faster decline in 
CD4+ T cells and therefore more rapid disease progression to AIDS compared to 
individuals infected with subtype A and D. A more rapid increase in viral load was also 
observed compared to subtype A infected individuals. Conversely, at least two studies 
reported that subtype C viruses were less fit, that is having reduced ability to adapt 
and replicate in a given environment, in comparison to other subtypes(28, 29). 
Furthermore, some studies have demonstrated subtype D as being the most 
virulent(30–32). However, the fact that subtype C viruses are globally dominant 
highlights the necessity to further characterise these viruses. Overall these studies 
show that genotypic features of HIV-1 subtypes contribute to phenotypic 
characteristics of the virus that determine disease progression and clinical outcomes 
of infection. 
 
1.4 The HIV-1 genome 
 
The entire HIV-1 genome comprises of approximately 9700 nucleotides. It is 
partitioned into nine viral genes (gag, pol, env, tat, rev, vif, vpr, vpu and nef) and is 
flanked by two identical LTRs (reviewed in detail in section 1.6). To minimise on 
genome length, the virus makes use of all three reading frames to encode the various 
protein sequences (Figure 1.2). The nine viral genes are divided into three classes: 
structural gens (gag; pol and env); regulatory gens (rev and tat) and accessory genes 





Figure 1.2 Gene map of the HXB2 HIV-1 strain. The three open reading frames are depicted. 
Positions of each of the nine genes are shown and gene subunits are indicated. Nucleotide start 
and end positions for genes are indicated at the top left and bottom right of each gene respectively. 




The gag gene encodes the major structural proteins of the viral core. There are four 
separate proteins encoded by gag, including the inner core membrane or matrix (MA, 
p17), the capsid protein (CA, p24), the nucleocapsid protein (NC, p7), which forms the 
nucleoprotein/RNA complex, and p6, which is involved in particle release(33). p7 and 
p6 are separated by p1, which is responsible for frameshifting into pol during 





The viral catalytic enzymes are encoded by pol. Protease (PR, p12) is responsible for 
proteolytic cleavage of precursor proteins; reverse transcriptase (RT, p51) is 
responsible for conversion of the viral RNA to DNA; RNase H (p15) for degradation of 
the viral RNA during reverse transcription, and Integrase (IN, p32), which facilitates 




Env consists of two glycoproteins that make up the viral envelope; gp120 (SU, surface 
glycoprotein), which contains the binding sites for the CD4 and CCR5/CXCR4 cell 
receptors, and gp41 (TM, transmembrane glycoprotein), which is responsible for 
viral/cell membrane fusion. These proteins associate in a covalently-bound trimeric 





The viral trans-activator of transcription protein, Tat, is the most essential viral protein 
for efficient HIV-1 gene expression. Tat is encoded on two separate exons in the viral 
genome and is one of the first genes expressed during infection. Tat acts by binding 
to the trans-activation response loop/element (TAR) located within the LTR and 





Rev is a highly conserved regulatory factor which is responsible for HIV-1 partially 
spliced and unspliced mRNA export and stabilisation from the nucleus to the 




The viral infectivity factor (Vif) protein enhances infectivity but does not directly 
influence replication. Vif binds the human cytidine deaminases APOBEC3G/F 
inhibiting their incorporation into the viral particle. In the absence of Vif, these host 
factors deaminate the (-)strand of viral transcripts resulting in incorporation of multiple 




Viral protein R (Vpr) is another viral accessory factor incorporated into the viral particle. 
Vpr acts in the nucleus of infected cells and prevents cell division by arresting the cell 
in the G2 phase of the cell cycle in which the HIV-1 LTR was found to be most active. 
This protein is also thought to affect the early stages of the viral life cycle i.e. entry, 





Viral protein U (Vpu) is an accessory integral membrane protein involved in 
antagonising the action of human cell CD317 tetherin, a host restriction factor that 
tethers viral particles to the cell membrane. Vpu is therefore essential for the release 
of newly produced viral particles out of infected cells(46). Furthermore, it has been 
shown that Vpu is responsible for targeted degradation of newly synthesised CD4 




The negative factor (Nef) protein is involved in multiple functions of HIV-1 
pathogenesis and is required for successful spread of viral infection, and also 
contributes to disease progression. Specifically, Nef contributes to downregulation and 
degradation of CD4 and MHCI complexes on the cell surface membrane preventing 
detection of infected cells by the host immune system(48). Additionally, Nef interacts 
with a number of signalling molecules within an infected cell that are collectively 
capable of inducing T cell activation in a CD4 independent manner, thus producing a 
cellular environment optimal for viral production. Nef has also been implicated in 
contribution to viral spreading by upregulation of receptors on dendritic cells which 
capture viral particles and facilitate transfer to uninfected CD4 cells(49, 50). 
 
1.5 The HIV-1 life cycle 
 
Each HIV-1 particle is enveloped with two copies of single-stranded RNA (ssRNA) and 
a number of viral enzymes including PR, RT and IN, amongst other viral proteins such 
as NC, all encapsulated within the core region of the virus(51). HIV-1 virions primarily 
target CD4+ T cells for infection(52, 53). The virions gain access to the cells by initial 
attachment of the viral gp120 Env protein to the CD4 cell surface receptor(54). 
Attachment of gp120 induces a change in conformation allowing further binding of the 
virus to either the CCR5 or CXCR4 chemokine receptors on the cells(55, 56). A 
secondary viral Env protein, gp41, facilitates fusion of the cell membrane and viral 
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envelope, which in turn allows the entry of the capsid(57). As the capsid enters CD4+ 
T cells, it undergoes uncoating to release its contents.  
 
The (+)strand ssRNA is converted into double-stranded DNA (dsDNA) by the 
packaged HIV-1 enzyme, RT. Reverse transcription takes place in the cytoplasm 
within the reverse transcription complex (RTC), a multiprotein complex which protects 
the viral genome and proteins from host anti-viral responses(58). Reverse 
transcriptase is error prone and therefore incorporates mutations during this 
process(59). Upon completion of viral DNA synthesis, the RTC matures into the 
preintegration complex (PIC) via protein re-arrangement(58). The PIC is then actively 
imported into the nucleus where viral DNA is integrated into the host chromosome by 
the viral enzyme, IN (60, 61). 
 
Once integrated, the HIV-1 DNA (genome) is referred to as a provirus and is able to 
replicate and initiate transcription from the 5’ LTR to produce viral transcripts. Initial 
transcription relies on the use of the host T cell machinery, however in the absence of 
Tat, transcription is hindered and elongation of transcripts is inefficient(40). The viral 
Tat protein is expressed off of initial transcripts and binds to the TAR loop of the LTR, 
potently upregulates the synthesis of full length viral transcripts stabilising elongation 
by recruitment of other cellular factors(62, 63). Hence a positive feedback loop is 
established. 
 
Subsequently, viral mRNA (sliced and unspliced) is exported from the nucleus to the 
cytoplasm. Here the spliced mRNA is translated into the polyproteins and processed 
into the proteins necessary for production of a new viral particle by the viral PR. These 
proteins together with unspliced viral RNA are transported to the cell plasma 
membrane and assemble into an immature viral particle with a partial envelope where 
the matrix and capsid structures are not completely cleaved. This immature particle 
pushes its way out of the CD4 T cell in a process termed budding, where envelope 
assembly is completed. The viral protein PR is then activated to complete processing 
of remaining polyproteins and rearrangement of the Matrix and Capsid structural 
proteins takes place thereby producing a mature infectious HIV-1 particle(51). This 
pathway of the HIV-1 life cycle is termed the lytic cycle. 
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Alternatively, HIV-1 may enter the lysogenic cycle upon infection of a CD4+ T cell. 
Integration takes place as described as above, however the provirus simply lies 
transcriptionally silent, or latent, within the host cell and no new viral particles are 
produced despite the provirus being capable of doing so(64). 
 
The establishment of viral latency requires the suppression of HIV-1 transcription(65). 
As HIV-1 transcription is dependent on the LTR, and LTR activity varies based on its 
genotype, it is possible that activity of the LTR can have a direct effect on the 
establishment of latency of a virus(66). Latency will be discussed in detail in section 
1.7. 
 
1.6 The HIV-1 Long Terminal Repeat (LTR) 
 
1.6.1 Reproduction, Structure & Function 
 
The integrated proviral LTR consists of three discreet segments, the unique 3’ (U3), 
repeat (R) and unique 5’ (U5) regions(67, 68). When in RNA form, the HIV-1 genome 
is flanked by two partial LTR sequences, an R and U5 region on the 5’ end and a U3 
and R region on the 3’ end (Figure 1.3A). During the process of reverse transcription, 
prior to integration, two identical complete LTRs are generated on either end of the 
resulting dsDNA sequence. The steps of this process are illustrated in Figure 1.3 A-H. 
 
This complex process was described by Huber et al. and Esposito et al. (69, 70). 
Briefly, HIV-1 replication is initiated by tRNA hybridisation to the primer binding site 
(PBS) on the (+)strand RNA at the end of the 5’ U5 region. The (-)strand is extended 
from the bound tRNA in the 3’ direction to the end of the 5’ R region by the RT-
associated DNA polymerase(Figure 1.3A). The R and U5 regions of the (+)strand are 
subsequently degraded by viral RNAse H (Figure 1.3B). The newly synthesised (-
)strand fragment is therefore free to move to and hybridise with the complimentary R 
region at the 3’end of the RNA (+)stand in a process known as the first strand transfer. 
This hybridised fragment behaves as a primer and synthesis of the (-)strand by DNA 
polymerase is carried out as far as the PBS at the 3’ end of the RNA (Figure 1.3C).  
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Following synthesis, the entire template RNA strand is RNAse H digested with the 
exception of two purine rich regions upstream of the U3 region, known as polypurine 
tracts (PPTs), which allows segments of the (+)strand to remain bound to the (-)strand 
(Figure 1.3D). DNA synthesis takes place using these (+)strand segments as a primer 
and the fragment is extended in the 3’ direction thus producing two fragments, one 
near the centre region of the HIV-1 genome and the other including the U3, R and U5 
(including the PBS) regions (Figure 1.3E). RNAse H degrades the RNA portion of 
these RNA:DNA hybrids releasing the terminal (+)strand fragment (Figure 1.3F) and 
a second strand transfer takes place. The newly synthesised fragment hybridises with 
the PBS on the 3’ end of the (-)strand. DNA synthesis of the (-)strand is completed 
towards the 3’ end of the RNA using this (+)strand fragment as a template. Finally, the 
(+)strand is extended to the 3’ end of the genome making use of the hybridised 
fragment and the central segment as primers(Figure 1.3G). 
 
Ultimately, the product of these processes is an integration competent, dsDNA 
molecule encoding the entire HIV-1 genome, flanked by two identical 634bp LTR 
sequences each comprising of a U3, R and U5 region (Figure 1.3H). Of importance, 
due to the strand transfers, genetic mutations within the 3’LTR are therefore ultimately 
introduced into the 5’LTR sequence. 
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Figure 1.3 Schematic representation of LTR regeneration during viral reverse transcription. 
 
Once the complete HIV-1 proviral genome has integrated into the host cell genome, 
the two LTRs, despite having identical nucleotide sequences, perform different 
functions. The 5’LTR acts as the HIV-1 promoter and harbours the transcriptional start 
site during viral replication whereas, the 3’LTR encodes a large portion of the nef gene 
and contains the necessary nucleotide sequence responsible for termination of 
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transcription and post transcriptional modification such as polyadenylation(67, 71). We 
will focus here on the function of the 5’LTR as a promoter and its role in HIV-1 latency. 
 
The 5’LTR sequence provides a binding/interaction region for a plethora of 
transcription factors and other proteins that influence transcription initiation and 
maintenance and promoter activity. The TAR element is contained within the R region 
of the LTR. This is the region where transcription is initiated and where the viral Tat 
protein binds in concert with the positive transcription elongation factor b (P-TEFb) 
complex composed of Cyclin T1 (CycT1) and cyclin dependent kinase 9 (CDK9)(72) 
(section 1.7.1.4) (Figure 1.4). 
 
 
Figure 1.4 Interaction of Tat and the P-TEFb complex with the HIV-1 TAR loop. Tat binds to 
a U-C-U bulge region and the Cyclin T1 subunit of the P-TEFb complex binds to top of the loop. 
Figure adapted from Karn, 2000(40) 
 
The complete LTR is 634bp in length and is assigned nucleotide (nt) positions relative 
to the transcriptional start site hence, the TAR element spans from nt +1 to +60(73). 
Three other functional regions have been designated within the U3 region, namely the 
modulatory (nt -454 to -104), enhancer (-105 to -79) and core promoter (-78 to -1) 
regions (Figure 1.4). These regions are classified based on their combinatory effect 
P-TEFb
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on promoter activity and viral genome expression(67, 74, 75). A fragment of the 
modulatory region was identified, by deletion and mutational analysis, to reduce 
expression of the LTR and was therefore designated as the negative regulatory 
element (NRE) extending between nt -340 and -184(76). These elements of the LTR 
are discussed in greater detail in the next section. 
 
1.6.2 Organisation of transcription factor binding/functional sites 
 
For the most part, LTR functional sites are conserved across HIV-1 group M subtypes. 
However, minor differences between subtypes exist which can impact the replicative 
capacity and fitness of each virus(77, 78). Most studies to date have focused on 
characterising the functional binding sites of subtype B LTR sequences (75, 79). The 
functions and positions of cis-regulatory binding sites within the HIV-1 LTR are 
illustrated below (Figure 1.5). An overview of each well-characterised site and its 






Figure 1.5 Schematic representation of approximate putative binding sites of well characterised cis-regulatory/transcription factor binding sites in the 
5’LTR of HIV-1. The U3, R and U5 regions and regions of functional sites are indicated by coloured boxes. The transcriptional start site is indicated at nucleotide +1 
at the U3 and R region junction.




































































1.6.2.1 The core promoter element 
 
The core promoter element comprises of the initiator element, which overlaps with the 
start of the TAR region, and the canonical TATA box promoter element to which the 
TATA binding protein (TBP)/transcription factor II D (TFIID) binds (Figure 1.5), 
initiating formation of the viral pre-initiation complex (PIC)(80). Subunits of the PIC 
bind directly to the core promoter region upstream of the TAR element. Three tandem 
specificity protein 1 (Sp1) sites also lie within the core promoter region upstream of 
the TATA box(81). Binding of the Sp1 protein to these sites has a positive effect on 
viral transcription, via recruitment of histone deacetylases (HDACs), and has been 
found to be essential for both basal and Tat-induced viral gene expression(82–84). An 
activator protein 4 (AP-4) binding site was also found within the core promoter, directly 
downstream of the of the TATA box(85). Interestingly, Imai et al.(86) demonstrated 
that binding of AP-4 to this site represses HIV-1 expression by competitively blocking 
TFIID binding to the TATA box and in addition, recruiting histone deacetylase 1 
(HDAC-1). 
 
1.6.2.2 The enhancer element 
 
Immediately 5’ of the core promoter, is the LTR enhancer region (Figure 1.5). This 
region primarily comprises of one, two or three adjacent, conserved nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) protein binding sites 
depending on the HIV-1 group M subtype. Of note, the majority of HIV-1 subtype C 
LTRs contain three NF-κB binding sites and have been found to have the highest 
promoter activity compared to other subtypes(87, 88). In addition, the acquisition of a 
fourth NF-κB site within the enhancer region has been reported in viruses from 
Southern Indian infected patients and was found to confer higher transcriptional 
activity within subtype C viruses(89). 
 
NF-κB binding sites are the most well characterised of the HIV-1 LTR elements, and 
the binding of NF-κB is considered one of the most essential steps in HIV-1 
expression(74, 88, 90). NF-κB, in its active form, binds to the LTR as a p65/p50 
heterodimer protein complex(91). Protein interactions between the p65/p50 
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heterodimer and molecules of Sp1 form as NF-κB binds to the LTR. These coordinated 
interactions are essential for enhancer functionality(92). Importantly, the binding of 
NF-κB is involved in recruitment of elements of RNA Polymerase II (RNAPII) complex 
to the transcription initiation site(93). Specifically, NF-κB was shown to recruit 
Transcription factor II Human (TFIIH), a transcription factor that phosphorylates 
RNAPII leading to promoter clearance(94). Furthermore, NF-κB contributes to 
chromatin remodelling where the p65 subunit of the heterodimer recruits the histone 
acetyltransferases (HATs), CREB-binding protein (CPB) and p300. HAT-driven 
acetylation of specific histones results in the enhancement of viral gene 
expression(91, 95, 96). Sequestering of CBP and p300 by NF-κB is also important in 
Tat-driven HIV-1 transcription. These HATs directly acetylate Tat in a process that has 
been shown to be important in Tat trans-activation of the LTR(97). 
 
An additional cellular transcription factor, nuclear factor of activated T cells (NFAT), is 
capable of binding to the NF-κB binding site within the LTR enhancer element as the 
two transcription factor recognition sequences overlap(98). NFAT is also capable of 
recruiting CBP and p300 to induce transcriptional activation and enhance HIV-1 gene 
expression(99, 100). Due to the overlapping recognition sites, binding of these two 
factors cannot take place simultaneously. 
 
Finally, an activator protein 1 (AP-1) binding site has been reported upstream of the 
NF-κB site within the enhancer element. Conservation of this binding site has been 
shown to be important in the ability of the virus to establish latent infection(101). 
 
1.6.2.3 The modulatory region 
 
The modulatory region lies at the 5’ end of the U3 region in the LTR (Figure 1.5) and 
contains recognition sequences for a wide range of regulatory factors. Binding of 
transcription factors to some of these sites results in positive regulation of transcription 
whereas others have an inhibitory effect. Most positive regulatory sites within the 
modulatory region are required for HIV-1 transcription but are not as essential as those 
mentioned in sections 1.6.2.1 and 1.6.2.2(79). 
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In subtype B LTRs, three CCAAT/enhancer binding protein (C/EBP) sites lie within the 
modulatory region, one at the extreme 3’ end of the modulatory region and the other 
two further upstream(102). However, in subtype C viruses, the extreme 3’ site does 
not exist, but instead, has been replaced with the extra NF-κB site described in section 
1.6.2.2, and the other two C/EBP sites lie further upstream in the LTR. These sites 
have been assigned as C/EBP upstream site 1 and 2 (C/EBP U1 and C/EBP U2) and 
lie between nt -259 to -247 and -446 to -433 relative to the transcriptional start site 
respectively(103, 104). In subtype B viruses, C/EBP has been shown to interact with 
the p65 subunit of NF-κB and contributes to both basal and Tat-induced transcriptional 
enhancement in macrophages and monocytes but this has not been demonstrated in 
CD4+ T cells(105–108). The specific role of the C/EBP sites within subtype C viruses 
has not been well characterised. 
 
A lymphoid enhancer-binding factor 1 (LEF-1) binding site has been described 
between nt -142 and -122 in the modulatory region(75, 109). Binding of the LEF-1 
protein to this site is thought to induce disruption of the chromatin nucleosome and 
interacts with HATs recruited by NF-κB. Furthermore, LEF-1 promotes bending of DNA 
and interacts with Sp1 and also facilitates interactions and correct positioning between 
other regulatory factors(109–112). Therefore LEF-1 has been classified as a positive 
regulator of HIV-1 expression. 
 
Continuing upstream, a binding site for the E-twenty six 1 (Ets-1) transcription factor 
lies between nt -149 and -142 in the LTR(109, 113). Additionally, a binding site for the 
upstream stimulatory factor 1 (USF-1) binds to an E-Box consensus sequence found 
between nt -166 and -161. It has been demonstrated, that interaction between these 
two proteins is necessary for them to bind to the LTR, and that their cooperative 
binding enhances viral gene expression. Ets-1 and USF-1 also contribute to bending 
of the LTR DNA, with Ets-1 interacting with LEF-1, to promote interactions of proteins 
within the PIC, such as Sp1 to aid in recruiting basal transcriptional machinery(109, 
111, 114, 115). Interestingly, it was more recently demonstrated that overexpression 
of an alternatively spliced form of the Ets-1 protein was capable of inducing HIV-1 
transcription from latently infected resting CD4+ T cells from patients on therapy 
independently, without causing T cell activation(116). This demonstrates the 
importance of the Ets-1 factor in positive regulation of the LTR. 
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Interestingly, the USF-1 protein has also been shown to form a heterodimer with USF-
2 and is collectively known as Ras response element binding factor 2 (RBF-2)(117). 
This heterodimer binds to a region of the LTR termed RBEIII which overlaps with the 
LEF-1 recognition site and is found between nt -131 to -121(118). RBF-2 binds to the 
E-box described above more efficiently than RBEIII, however a co-factor General 
Transcription Factor II-I (TFII-I), initially identified as an initiator binding protein, is 
essential for promoting this interaction. Chen et al.(117) demonstrated that binding of 
RBF-2 to RBEIII induces latent integrated viral expression in a T cell activation 
dependent manner, specifically in response to activation by the Ras/mitogen activated 
protein kinase (MAPK) cascade(119, 120). No published reports have detailed any 
interaction between LEF-1 and RBF-2. 
 
Two more NFAT DNA recognition sites were found in the modulatory region of the U3, 
one between nt -254 and -216 and another between nt -303 and -288, via DNA foot-
printing experiments. However, NFAT associated more weakly to these upstream sites 
compared to those in the enhancer region(121). The effect of NFAT binding to these 
upstream sites has not been well characterised as increased levels of and higher 
affinity binding of NFAT has been demonstrated in activated T cells(122). However, 
there is evidence to show that HIV-1 transcription is not significantly affected by NFAT 
binding(123). 
 
A glucocorticoid receptor (GR) binding site was originally identified, via mobility shift 
assays, between the two NFAT recognition sites between nt -264 and -269(124). It 
was subsequently demonstrated that addition of the glucocorticoid, dexamethasone, 
had a negative regulatory effect on viral expression in T and B lymphocytic lineages. 
Furthermore, this suppression was dependent on the LTR having an intact GR(125). 
Despite this discovery, the specific interactions of this region and the PIC are yet to 
be elucidated. 
 
A binding site for the proto-oncogene encoded c-Myb (c-myeloblastosis) protein lies 
between nt -304 and -299. Binding of this protein was found to stimulate viral 
expression via trans-activation of the LTR(126, 127). Interestingly, the c-Myb protein 
is upregulated during mitogen dependent T cell activation, the state in which viral 
expression is at its highest, suggesting that this protein may form a direct link between 
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the cell activation and degree of viral expression(128). The c-Myb consensus binding 
sequence has additionally been implicated in the formation of other protein complexes 
associated with transcription(129). 
 
Finally, two putative binding sites for both AP-1 and chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) are found at nt -352 to -324 and nt -306 and 
-285. However, studies have demonstrated that the AP-1 protein is incapable of direct 
interaction with these two sites, and the effect of AP-1 is unknown here(130, 131). The 
COUP-TF protein reportedly binds directly to the nt -352 to-324 region and induces 
transcriptional activity. However, COUP-TF additionally is capable of positively or 
negatively mediating viral expression, in a cell type-specific manner, via interaction 
with Sp1 in the core promoter element(132, 133). 
 
1.6.2.4 Downstream elements in the R and U5 region 
 
A number of cis-regulatory binding sites are also present downstream of the 
transcriptional start site and cellular factors binding here interact with the transcription 
initiation complex and regulate its activity. 
 
Firstly, a late SV40 factor (LSF) binding site overlaps the transcriptional start site 
spanning from nt -10 to +27. Binding of LSF is thought to play an important negative 
regulatory role in HIV-1 expression as it recruits a secondary factor, Yin Yang 1 (YY1), 
which in turn recruits HDAC-1 which has been shown to contribute to Tat activation 
inhibition(134–136). 
 
Further downstream, an additional three AP-1 binding sites were identified at nt +85 
to +93 (site I), nt +121 to +138 (site II), and nt +153 to +161 (site III) via footprinting 
analysis(137, 138). Mutation of these sites, especially site I and II, was shown to 
decrease HIV-1 basal expression and viral infectivity(139, 140). 
 
Finally, another NFAT binding site was discovered in the U5 region, between nt +158 
and +175(137). In addition to recruitment of stimulatory co-factors (section 1.6.2.2), 
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prevention of NFAT binding in this region reduced Tat-induced LTR activity, 
suggesting interplay with Tat(100, 141). 
 
This is not an extensive list of all regulatory transcription factor binding sites that have 
been reported within the LTR. However, sites not listed here are poorly characterised, 
particularly in subtype C viruses, and their effect on viral transcription is unclear. 
Furthermore, the role of the LTR in HIV-1 latency is under-characterised. We will first 
review the literature on HIV-1 latency below before reviewing the contribution of the 
LTR to this latent state. 
 
1.7 HIV-1 latency 
 
HIV-1 has the ability to stably integrate its genetic material into a host cells genome 
(section 1.5). This proviral DNA can lie dormant, in a state known as latency until it is 
reactivated to produce new viruses later on during infection. Primary evidence for HIV-
1 latency was first demonstrated by Folks et al.(142), where viral gene expression, in 
cells that survived initial infection and were unable to produce virus under normal 
conditions, was induced after exposure to a number of T cell activation compounds. 
 
HIV-1 infects CD4+ T cells which are in an immune activated state, which is conducive 
to novel HIV-1 production, often resulting in cell death(143–145). Therefore, it is 
presumed that the phenomenon of latency occurs when a target activated CD4+ T cell 
is infected, but does not experience cell death despite production of virions within the 
cell, and instead reverts to a resting memory state(146, 147). However, a number of 
studies have provided evidence to demonstrate that these latently infected cells can 
arise from direct infection of resting CD4+ T cells(148–151). This population of infected 
resting memory cells constitutes the majority of the cellular latent reservoir(152). 
Seeding of this latent reservoir has been shown to take place early during the acute 
phase of infection, as early as three days post-infection(153, 154). Productive viral 
gene expression cannot occur in these resting CD4+ memory T cells, as the necessary 
transcription factors and other host factors essential for HIV-1 replication are not 
expressed(155). Conversely, studies have also demonstrated establishment of 
latency in actively proliferating CD4+ T cells(151, 156, 157), therefore, in addition to 
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the immune activation state of the infected host cell, a number of other molecular 
mechanisms contribute to establishing and maintaining HIV-1 latency, these will be 
reviewed in section 1.7.1. 
 
Latent proviral DNA does not produce new virus or viral proteins, and the immune 
system and current therapies are unable to detect, target or eliminate it (158, 159). In 
addition, resting CD4+ memory T cells persist in the infected individual for many years 
due to an extended cell half-life of over 3.5 years on average(160). Therefore, latent 
infection allows for HIV-1 to remain present for the entire lifespan of infected patients 
who are on therapy(161). The persistence of replication competent proviral DNA for 
long periods of time allows for rapid viral rebound from within a period of days up to 
approximately 12 weeks of ART interruption(10, 162, 163). Therefore, latency poses 
an immense barrier to a cure and also necessitates lifelong ART. 
 
1.7.1 Molecular mechanisms of latency 
 
A comprehensive understanding of how latency is established and maintained has not 
been demonstrated to date. This is largely due to the difficulty of studying latently 
infected cells as they are rare, occurring at an estimated rate of only 10-100 cells per 
million CD4+ T cells(164). Nevertheless, there is evidence to show that a number of 
molecular mechanisms and factors contribute to the establishment and maintenance 
of HIV-1 latency and these are reviewed in the sections below. 
 
1.7.1.1 Nature of integration 
 
It would be expected that, due to the diversity of the human genome, HIV-1 expression 
would be influenced by the specific locus into which the virus integrated. However, it 
is widely accepted that HIV-1 does not integrate in a random manner, but rather the 
virus is reported to integrate in expressed regions of the genome(165, 166). 
Furthermore, Han et al.(167) demonstrated that 93% of the integration sites sampled 
within resting memory CD4+ T cells resided in intronic regions of actively transcribed 
genes. This observation would seem counterintuitive considering the lack of viral gene 
expression from these resting memory cells. A number of mechanisms have been 
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proposed where the active transcription of host genes may interfere with viral gene 
expression resulting in latency, including steric hindrance, promoter occlusion and 
enhancer trapping. This interference can be influenced by the proximity of the viral 
genome to a host cell promoter or the orientation of integration of the virus(168, 169). 
 
Steric hindrance occurs when the HIV-1 genome integrates downstream of a host 
gene promoter in the same orientation. In this scenario, an RNAPII transcription 
complex from the host gene promoter reaches the HIV-1 5’LTR and dislodges a viral 
transcription pre-initiation complex thereby preventing viral expression. This 
displacement was demonstrated in two studies wherein specifically a reduction in 
binding of the Sp1 transcription factor to the HIV-1 LTR was observed(170). Contrary 
to these findings, a study by Han et al.(168) found that upstream transcription of host 
genes was capable of increasing HIV-1 expression during RNAPII read-through, if the 
virus was integrated in the same orientation. 
 
Alternatively, HIV-1 may integrate in the opposite orientation compared to a nearby 
host gene. In this instance, during elongation, an RNAPII complex from a host gene 
may collide with the RNAPII complex which initiated at the HIV-1 LTR resulting in early 
termination of one or both of the transcription complexes(171). This phenomenon is 
termed promoter occlusion(79). There is evidence to show that convergent RNAPII 
complexes do not actually displace each other, but rather simply stall at the site of 
collision and remain stable, suggesting that complete elongation from either RNAPII 
is not possible(172). Furthermore, integration in this manner can result in both DNA 
strands of the provirus being transcribed, leading to the production of double-stranded 
RNA molecules. These dsRNA molecules can be processed into small interfering RNA 
(siRNA) capable of preventing transcription by RNA interference, targeted degradation 
of mRNA transcripts via antisense RNA guides or siRNA associated DNA 
methylation(173–177). 
 
The final mechanism of suppression influenced by HIV-1 is known as enhancer 
trapping. This trapping effect takes place when the virus integrates in close proximity 
to a host cell gene. The upregulatory effect of the 5’LTR enhancer region is hijacked 
by the host gene preventing enhancement of viral expression, leading to a reduction 
or total repression of HIV-1 transcription(178, 179). 
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Overall, the collective influence of the nature of integration on HIV-1 latency is not well 
characterised and can be highly variable(180). It is likely that a range of other 
molecular mechanisms also contribute to viral latency. 
 
1.7.1.2 Epigenetic control and chromatin environment 
 
Chromatin is the molecular complex of DNA and proteins that forms chromosomes 
within cells and can be found in two general forms, euchromatin and 
heterochromatin(181–183). Briefly, euchromatin is typically gene-rich and less 
condensed allowing for active transcription of gene regions. Conversely, 
heterochromatin does not harbour many genes and is highly condensed. In this 
condensed state, gene expression is prevented as access to transcription factors 
essential for transcription initiation and elongation is hindered. 
 
Chromatin is composed of nucleosomes, where DNA is wrapped around histone 
octamers. In latently infected cells, two nucleosomes, nuc-0 and nuc-1, lie within the 
LTR upstream of the modulatory region and immediately downstream of the 
transcriptional start site respectively. These nucleosomes impose a transcriptional 
block by preventing RNAPII movement(184). Initiation of transcription necessitates the 
remodelling of nuc-1 to alleviate this block(185). 
 
A range of cellular proteins are capable of targeting histones and altering the state of 
this chromatin in a reversible epigenetic manner, which in turn alter gene expression. 
Histones associated with transcriptionally silent proviral DNA, within heterochromatin, 
are characterised by deacetylation and high levels of methylation of lysine residues in 
histones. These modifications aid in maintenance of the repressive state(186). 
Primarily, HDACs are recruited by cis-acting regulatory factors bound to the LTR 
(section 1.6) such as YY1, LSF, AP-4, C-promoter binding factor-1 (CBF-1) and the 
NF-κB p50/p50 homodimer(136, 187–189). Histone methyltransferases (HMTs) 
including, Enhancer of Zeste 2 (EZH2), suppressor of variegation 3–9 homologue 1 
(Suv39H1) and Euchromatic histone-lysine N-methyltransferase 2 (EHMT2/G9a) 
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methylate lysine residues in histones, which in turn recruits heterochromatin 
remodelling proteins(187, 190–192). 
 
Finally, direct methylation of DNA in close proximity of nuc-1 by DNA 
methyltransferases (DNMTs) has also been reported to contribute to HIV-1 latency 
establishment(193, 194). It was proposed that this methylation may either result in 
recruitment of HDACs or alternatively, directly inhibit binding of necessary 
transcription factors(195). Conversely, low levels of LTR methylation were observed 
in on-therapy patients suggesting that this mechanism may not play an important role 
in transcriptional silencing(196, 197). 
 
1.7.1.3 Availability of cellular transcription factors 
 
The HIV-1 LTR sequence contains binding sequences for several inducible regulatory 
cellular transcription factors (section 1.6.2). Many of these factors are essential for 
initial transcription of HIV-1, most notably NF-κB, NFAT and Sp1. NF-κB and NFAT 
are sequestered to the host cell cytoplasm in resting CD4+ T cells limiting initiation of 
transcription(198, 199). Furthermore Sp1 was downregulated in resting T cells 
compared to activated cells(200). 
 
1.7.1.4 Transcriptional control by Tat/P-TEFb 
 
During the second phase of HIV-1 transcription i.e. the Tat-dependent phase, much 
higher levels of transcription are observed(201). RNAPII and other complexes 
including TFIID, collectively the PIC, initiate RNA synthesis at the TAR region of the 
LTR(80). Soon after initiation this complex experiences promoter-proximal pausing to 
allow for 5’ capping of the nascent RNA strand before resumption of transcription(202). 
This continuation is hindered in HIV-1 by the negative transcription elongation factor 
(N-TEF) complex bound at the nuc-1 region (section 1.7.1.2), leading to the premature 
abortion of viral transcripts(203–205). Productive transcription/elongation of 
transcription takes place after expression and interaction of viral Tat with the TAR loop 
which recruits the cellular P-TEFb complex (CycT1 and CDK9)(72). 
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P-TEFb promotes transcription via phosphorylation of RNAPII and promoting 
dissociation of the N-TEF complex from the TAR loop(206, 207). Tat/TAR interaction 
additionally recruits other cellular cofactors such as the histone modifiers p300 and 
CBP presumably to maintain a conducive chromatin environment for transcription and 
may also contribute to assembly of the PIC(208, 209). Therefore, the action of Tat and 
P-TEFb cumulatively result in the promotion of efficient elongation and clearance of 
inhibitory factors. 
 
As described in section 1.5, a Tat positive feedback loop is established in HIV-1 
infection. Entry into latency is thought to be a consequence of disruption of this 
feedback loop by down-regulation of Tat expression(210). Interestingly, HIV-1 does 
not independently encode any genes that actively repress viral expression; instead 
this process relies mostly on cellular factors. 
 
P-TEFb activity is regulated in both resting and activated cells. In resting T cells, 
expression of the essential CycT1 subunit is heavily repressed via microRNA-
mediated mechanisms(211). CDK9 is constitutively expressed in resting cells, 
however it exists in an inactive form due to dephosphorylation of its regulatory 
activation loop(212). Therefore, P-TEFb cannot form or function efficiently in resting 
cells and transcription of HIV-1 is inhibited. 
 
In the absence of Tat in activated CD4+ T cells, P-TEFb subunits are present at high 
levels in their active form. However, the majority of P-TEFb is sequestered into a 
repressive complex known as 7SK small nuclear ribonucleoprotein (snRNP), 
rendering it inactive as it cannot be accessed by the LTR(213). When Tat is expressed 
in an activated cell, it is capable of disrupting the 7SK snRNP complex, liberating the 
P-TEFb complex allowing it to act on HIV-1 expression(214). Furthermore, another 
cellular protein BET bromodomain protein 4 (BRD4) is capable of recruiting P-TEFb 
from the 7SK snRNP complex, thus competing with Tat and resulting in viral 
repression(215). 
 
Therefore, P-TEFb exists in an active free form and an inaccessible form sequestered 




Taken together, is it clear that HIV-1 latency is a highly complex phenomenon with a 
plethora of mechanisms acting together to induce the latent state. 
 
1.7.1.5 Role of the LTR genotype in latency 
 
A role for the HIV-1 LTR, in the establishment of latency has been proposed. Two 
studies have directly implicated the genotype of the LTR in latency establishment(101, 
156). 
 
Firstly, Duverger et al.(101) identified an AP-1 binding sequence slightly upstream of 
the transcriptional start site within the LTR that varied across subtype isolates. They 
found that this sequence independently altered the proportion of cells that became 
latently infected by a particular isolate using mutational analysis and assessing the 
ability of these viral isolates to establish latency in an inducible reporter cell line. The 
4 nt motif in subtype B viruses showed reduced latency potential compared to the 7 nt 
counterpart found in subtype A or C viruses. Extension of this 4 nt motif to the 7 nt 
increased the latency potential of the infecting virus, whereas complete deletion of the 
motif impaired the latency potential of the virus. 
 
Secondly, Dahabieh et al.(156), confirmed that subtype level genotypic variance of the 
entire LTR influenced viral sensitivities to latency. Specifically, this group used a 
reporter-based model (described in detail in section 1.8.2.3) in which a CD4+ T cell 
line was infected with reporter viruses harbouring a subtype-specific LTR. It was 
demonstrated that the majority of cells were latently infected shortly after infection. 
Subtype D and F had the highest latency potential, with subtype AE displaying the 
lowest latency potential. A specific mechanism of LTR silencing or features of the LTR 
associated with higher latency potential were not defined in this study. 
 
Conversely, van der Sluis et al.(217), reported no major disparities in initial levels of 
latency across HIV-1 subtype LTRs, with the exception of subtype AE where lower 
levels of latent cells were observed upon infection. However, this study utilised a 
model which measured levels of p24 antigen i.e. products of HIV-1 particles, whereas 
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the aforementioned models directly measured the transcriptional activity of integrated 
provirus. 
 
1.8 Models for assessing HIV-1 latency 
 
A number of in vitro and in vivo models have been developed to mimic HIV-1 latency 
such that latently infected cells can be evaluated under a more controlled set of 
conditions. Examples of these models are discussed below. 
 
1.8.1 In vivo models 
 
It is possible to replicate/model HIV-1 latency in Simian Immunodeficiency Virus (SIV)-
infected non-human primates following administration of ART. Four studies have used 
different combinations of ART to lower the viral loads in infected macaques to similar 
levels of those in virally suppressed HIV-1 infected patients(218–221). In these 
animals, researchers were able to interrogate different anatomical regions to attempt 
to isolate replication competent virus, measure the effect of ART on frequencies of 
resting cells with replication competent virus and measure levels of viral DNA and RNA 
within resting infected cells. However, such experiments are expensive, time 
consuming and the viral latency phase is much shorter compared to that of humans. 
Another caveat is that SIV, despite having high similarity to HIV, is still genetically 
distinct and properties of the two viruses may differ(222, 223). 
 
A number of in vivo murine models have also been developed, where immuno-
deficient mice are humanized via human stem cell, tissue transplant or a combination 
of the two. These include the bone marrow-liver-thymus (BLT) SCID-hu (Thy/Liv) and 
T cell only mice (ToM)(224–226). These murine models allow for measurement of 
different properties of HIV-1 infection. All models produce functional human immune 
cells and are therefore capable of supporting HIV-1 infection and replication and 
establishment of latency. Furthermore, human cells in these mice have been shown 
to react similarly to drugs as they do in humans, and latently infected HIV-1 cells can 
be isolated from the models after viral suppression after ART treatment(227–229). Of 
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note, one model, the T cell only mice (ToM) was developed where mice have high 
levels of human T cells in all tissues and additionally, lack other antigen presenting 
cells including B cells, dendritic cells macrophages and monocytes(225). Therefore, it 
is possible to evaluate HIV-1 latency exclusively in T cells without interplay of other 
immune cells. 
 
Limitations of murine models include the small size and short lifespan of the mice 
meaning that minimal amounts of blood and tissue can be obtained from infected mice 
for study(230). Memory cell infection is also difficult to study in these models as the 
majority of human cells are naïve(222). There are also fundamental anatomical 
differences between human and mice tissue structure that may influence infection 
dynamics. Finally, in some cases animals can develop graft-versus-host disease(231). 
 
1.8.2 In vitro models 
 
A variety of in vitro latency models have also been developed which have number of 
advantages over the in vivo models described above. In general, these models are 
less expensive to maintain, and assays are faster and less tedious. Three such models 
are discussed below. 
 
1.8.2.1 Cell-line models 
A number of groups have developed cell-line based models of HIV-1 latency(232–
234). In these models, cells are chronically infected and little constitutive HIV-1 gene 
expression is observed. However, significant HIV-1 gene expression can be induced 
upon treatment of these cells with a variety of stimulating cytokines, mitogens and T 
cells activation compounds. These include the ACH-2, U1 and J∆K cell lines. These 
models have provided a system to study viral integration sites, mechanisms of viral 
latency and host gene expression post viral induction(204, 235–237). 
 
Despite the usefulness of these cell lines, their relevance and ability to truly represent 
viral latency within an infected patient has come under question. It was subsequently 
found that mutations within the tat gene and TAR region of the viral genome (section 
1.3) were responsible for the low levels of constitutive viral expression in ACH-2 and 
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U1 respectively(238, 239). Similarly, the latent phenotype of J∆K cells is due to the 
deletion of an NF-κB site within the LTR of the integrated infecting virus(234). 
 
Another cell-line based latency model, J-Lat, was later developed(240). In this model 
a T lymphocyte cell line, Jurkat, was infected with a full-length HIV-1 vector derived 
from a replication incompetent pseudovirus expressing green fluorescent protein 
(GFP) and Tat under the control of an LTR. Latently infected cells were enriched for 
by selection of cells with integrated virus that did not express GFP in the absence of 
activation, using fluorescence-activated cell sorting (FACS). Clones of these cells 
were expanded and were shown to express viral proteins and GFP after cell activation. 
A number of different stimuli were tested with this model to assess their reactivation 
potential on latency. Other studies have used the J-Lat cell-line to study aspects of 
transcription and interactions of cellular factors with the LTR in latent cells(188, 241). 
More recently, this cell line was used to show the efficacy of Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) mediated latency activation and the 
identification of the mammalian target of rapamycin (mTOR) complex and its influence 
on viral latency(242–244). 
 
Once again there are limitations to this model, due to it being established using a 
replication incompetent virus. J-Lat clones have single sites of integration that are not 
representative of infection in patients. Furthermore, for all cell-line models, cells 
constantly undergo replication and are in a state of cellular activation, whereas latently 
infected resting memory cells are long-lived and only experience low levels of 
proliferation(245, 246). Hence, verification of findings in cell-line latency models in 
primary cells is therefore necessary. 
 
1.8.2.2 Primary cell models 
 
A number of primary cell models have been developed wherein infection of activated 
CD4+ T cells is simulated in vitro. Of note, five different groups followed similar 
procedures to generate a population of latently infected cells(247–251). Firstly, CD4+ 
T cells were isolated from donors and activated via a number of mechanisms e.g. a-
CD3/a-CD28 antibodies in the presence of interleukin 2 (IL-2). Thereafter activated 
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cells were infected with replication competent viruses, HIV-1 derived vectors or 
pseudotyped viruses. Infected cells were then returned to a resting state over an 
extended culture period. The final step of obtaining a resting state in these cells is the 
most challenging, as cells are prone to death soon after activation unless cultured 
under specific conditions or cytokine milieu. Therefore, obtaining large populations of 
latently infected cells is difficult(252). Furthermore, in some cases cells still expressed 
some markers of activation, indicating that they may not be completely representative 
of latently infected resting memory cells. One group, Yang et al.(251) was able to 
circumvent some of these challenges by transducing their activated cells with a Bcl-2 
expressing vector. This acts as an anti-apoptotic protein allowing for long term culture 
of infected activated cells and establishment of latency in the absence of modified 
growth conditions. 
 
Despite this, all groups were able to demonstrate increased HIV-1 expression in their 
“resting” infected cells after activation the addition of Tat or latency reversing agents, 
suggesting latency had been established in some cells. These models have proven 
useful in reactivation studies and determination of factors contributing to viral latency. 
 
Other models have been developed where resting CD4+ T cells are directly 
infected(253, 254). Isolated memory CD4+ T cells were directly infected with 
replication competent HIV-1 by spinoculation. This eliminates the challenging process 
of allowing activated cells to transition to the resting state and latency is established 
within a few days of infection. Nonetheless, this model has limitations. Very few cells 
are infected as resting cells are not highly susceptible to infection due to unfavourable 
transcription conditions, and the pool of latently infected cells does not survive for 
extended periods of time without culturing cells in the presence of cytokines as 
mentioned above(155, 222). 
 
Overall, both active and resting T cell HIV-1 infected latency models provide an in vitro 
method of assessing properties of latently infected cells which more accurately 
represents the in vivo conditions of infection than clonally derived cell-lines. 
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1.8.2.3 Plasmid reporter constructs 
 
A number of HIV-1 reporter plasmids have been developed with a reporter gene 
inserted within the HIV-1 genome under the control of the HIV-1 LTR(255, 256). These 
plasmids are used to generate viruses that are, in turn, used to infect T cell lines or 
primary cells, and the activity of the infecting virus can be monitored by measurement 
of the reporter protein. Essentially, latently infected cells can be identified by the 
absence of the reporter protein. Burke et al.(255) developed a construct harbouring 
an enhanced-GFP(eGFP):Luciferase fusion gene. In this model, transcriptionally 
inactive immature CD4+ thymocytes were infected with a pseudovirus generated from 
the construct. eGFP expression was measured by flow cytometry after infection as 
these cells matured. A subset of cells was stimulated, and the proportion of latently 
inducible cells could be measured as eGFP expression increased. Furthermore, these 
inducible latently infected cells underwent purification by FACS and were used to study 
LTR regulation. 
 
Sorting of cells to obtain the latently infected subset can be tedious and time 
consuming. Therefore, other HIV-1 based viral reporter constructs have been 
developed with two independent reporter genes, one under the control of a 
strong/constitutive promoter and another under the control of the viral LTR(256). The 
constitutive reporter acts as an indicator of successful infection and integration of the 
construct whereas the LTR driven reporter denotes viral activity. Calvanese et al.(256) 
developed two models where the HIV-1 nef gene was substituted with either an 
mApple or eGFP reporter and a spleen focus forming virus (SFFV)p-eGFP or 
Elongation factor-1 alpha (EF1a)-mCherry cassette inserted downstream, 
respectively. A population of both productively and latently infected cells were 
identified simultaneously. Chavez et al.(151) made use of the eGFP/EF1a-mCherry 
to demonstrate direct establishment of latency in both active and resting CD4+ T cells. 
 
An additional HIV-1 based viral reporter was developed by Dahabieh et al.(156), the 
Red-Green-HIV-1 (RGH) model. This model will be referred to throughout this thesis. 
The original plasmid construct, pRGH (LAI-gagiGFP-CMVmCherry-deltaEnv), 
 35 
contains a full-length replication competent, infectious HIV-1 subtype B LAI molecular 
clone(257) (Figure 1.6). 
 
 
Figure 1.6 Schematic depiction of the RGH plasmid. pRGH is derived from pLAI full length 
replication competent, infectious HIV-1 subtype B LAI molecular clone. An eGFP gene has been 
inserted in-frame between the matrix and capsid regions of the gag gene. The env open reading 
frame was disrupted by a single base pair deletion at position 7136 resulting in a frameshift. The 
nef gene has been partially deleted and replaced with a CMVIE driven mCherry gene construct. 
Figure obtained at: http://www.aidsreagent.org/support_docs/12427_map.pdf. 
 
The infectious molecular clone was modified by the authors as follows for the purpose 
of investigating latency:  
• Firstly, the LAI gag gene was replaced by a gag-eGFP fragment from the Gag-
iGFP NL4-3 clone, where an eGFP gene was inserted in-frame between the 
matrix and capsid regions(258). Insertion of the reporter gene at this position 
leads to production of a Gag-eGFP-capsid fusion protein and results eGFP-
labelled viruses. As the expression of Gag-eGFP is dependent on transcription 
from the HIV-1 LTR promoter, detection of this protein within infected cells is 
indicative of HIV-1 expression and can therefore be used to identify actively 












































• Secondly, the nef gene was partially deleted and replaced with a 
cytomegalovirus (CMV) promoter-driven mCherry gene construct, amplified 
from the pcDNA3.1+-mCherry(259). CMVIE is a strong promoter, and capable 
of constitutive expression(260, 261). Therefore, mCherry is expressed, in the 
host cell, post-integration independently of transcriptional activity of the HIV-1 
LTR and can therefore be used to detect cells with successfully integrated virus. 
• Finally, the env open reading frame was disrupted by a single base-pair deletion 
at position 7136 resulting in a frameshift. This deletion renders the env gene 
inactive, hence viruses generated from this construct are capable of infecting 
cells, integrating into the host cell genome and expressing viral proteins, but 
they are incapable of producing new infectious viral particles. Therefore, further 
rounds of infection are not possible. 
 
1.9 Latency reversing agents 
 
Currently, strategies to clear the latent reservoir focus on induction of viral gene 
expression while an infected individual is still on therapy such that the infected cells 
will be recognized and killed by the immune system, but infection of new cells will not 
occur. Chromatin structure, methylation state of DNA and the presence/availability of 
a number of transcriptional factors and activators are all mechanisms that play a role 
in maintenance of HIV-1 latency (section 1.7). A number of latency reversing agents 
(LRAs) have been developed to target these molecular mechanisms of latency in the 
hopes of reactivating latent provirus to purge the latent reservoir and ultimately cure 
an infected individual. 
 
1.9.1 Histone Deacetylase inhibitors (HDACis) 
 
HDACis are compounds that inhibit HDACs recruited to the HIV-1 LTR during latency 
and therefore result in relaxation of chromatin facilitating transcription and outgrowth 
of proviruses(185). This has been the major focus of latency reversal in clinical trials, 
a number of which are still in progress(262). Multiple studies have demonstrated 
initiation of transcription in both latently infected T cell models and primary cells 
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isolated from on-therapy patients. Examples of this class of LRAs include valproic acid 
(VPA), Vorinostat (SAHA) and Trichostatin (TsA)(185, 263, 264). These compounds 
have been well characterised in the context of anticancer therapies and some have 
already been approved by the Food and Drug Administration (FDA) for other 
treatments(265). However, an in vitro study using SAHA demonstrated that the 
majority of proviral latently infected cells was not reactivated upon HDACi treatment 
(266). 
 
1.9.2 Histone methyltransferase inhibitors (HMTis) 
 
These compounds also act to prevent the formation of heterochromatin via inhibition 
of H3K9 methylation (section 1.7.1). Two compounds BIX01294 and chaetocin have 
been shown to inhibit the action of G9a and Suv39H1 respectively in vitro and have 
been able to induce viral outgrowth from latently infected cells isolated from on-therapy 
patients. Furthermore, they are capable of enhancing the effect of the HDACis 
mentioned above(187, 267). 
 
1.9.3 DNA methyltransferase inhibitors (DNMTis) 
 
The degree that direct DNA methylation plays in latency is somewhat debated (section 
1.7.1.2). However once again these compounds are hypothesised to prevent 
formation of transcriptional inhibitory heterochromatin and allow for efficient viral 
transcription. There is some evidence to demonstrate that the DMNTi Decitabine in 
addition to the T cell activation agent Tumour Necrosis Factor alpha (TNF-a) is 
capable of HIV-1 latency reactivation in certain latently infected cell lines(268). 
 
1.9.4 Protein Kinase C activators 
 
The protein kinase C (PKC) pathway is a cellular cascade induced upon T cell 
activation that stimulates production of a number of HIV-1 upregulatory transcription 
factors such as NF-κB, NFAT and AP-1(269–271). Therefore, stimulation of this 
cascade induces HIV-1 expression by binding of these factors to the LTR(272). Many 
PKC activators have been developed including phorbol 12-myristate 13-acetate 
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(PMA), prostratin, 12-deoxyphorbol 13-phenylacetate (DPP) and bryostatin. These 
compounds have been shown to be highly effective at reactivating latency in T cell 
models and PBMCs and astrocytes from on therapy HIV-1 infected individuals(273–
275). However, some PKC activators induce a number of unwanted effects such as 
tumour promotion and upregulation of a range of other cytokines that can cause 
cellular toxicity(276–278). This is due to the non-specific nature of these compounds 
on T cell activation. 
 
1.9.5 Positive transcription elongation factor b activator 
 
The P-TEFb protein is an essential protein complex in viral expression (section 
1.7.1.4). Hexamethylene bisacetamide (HMBA) activates HIV-1 transcription by 
facilitating release of P-TEFb from the 7SK snRNA allowing it to act on the LTR(279). 
HMBA has shown limited efficacy at reversing latency in a T cell model(251). 
Furthermore, this compound did not induce CD8+ T cell recognition after treatment of 
infected cells(280). Another compound JQ1s, capable of reactivating HIV-1 
expression in latently infected cell lines, was developed which has an inhibitory effect 
on Brd4, the complex which competes for P-TEFb(281). 
 
Despite some of these compounds showing some efficacy in reactivating latent 
proviral DNA in infected cells, to date there has not been any evidence to show that 
they are capable of depleting the latent reservoir. It has been demonstrated that 
combinations of some of these LRAs, used on latently infected cells isolated from on-
therapy patients, induced higher levels of HIV-1 transcription than when used 
alone(282). This suggests that combination reactivation therapy may be necessary to 
effectively reverse latency. Interestingly, the size of the latent reservoir has been 
implicated in the reactivation capacity of some of these latency reversing agents(283). 
Therefore, understanding potential factors contributing to latency establishment may 




HIV-1 latency represents the greatest barrier to a cure. The HIV-1 LTR, serves as the 
viral promoter element that regulates HIV-1 gene transcription. Subtype level 
genotypic variation within the LTR, has been implicated in influencing the 
establishment of viral latency and has been shown to affect the proportion of infected 
cells in which viruses enter the latent state. Furthermore, variation of the U3 region of 
the LTR has been shown to influence the transcriptional activity of the virus(77, 284). 
The U3 region encodes regulatory functional sites to which host cell factors such as 
transcription factors and cytokines as well as the viral protein Tat, which upregulates 
LTR promoter activity, bind. There is limited information on the role of the LTR, and 
more specifically of subtype C viruses, which dominate globally, in viral latency. 
 
Further understanding of the molecular mechanisms that influence latency is therefore 
vital in developing strategies to target latent reservoirs as part of cure and remission 
strategies. 
 
This study provides insights into the influence that the subtype C LTR has on 
establishing latency during early HIV-1 infection. More specifically it characterises the 
influence of the LTR genotype on a participant level. In addition, this study investigates 
potential correlates of LTR-driven latency potential including Tat-induced 
transcriptional activity. 
 




To determine the influence of HIV-1 LTR genotype and transcriptional activity on the 





1. Generate a panel of LTR-pseudotyped viruses from acutely-infected individuals 
from the CAPRISA 004 cohort 
2. Determine the latency potential of each pseudovirus in a CD4+ T cell-line 
3. Measure Tat-induced promoter activity of participant LTRs using luciferase 
reporter constructs 
4. Evaluate potential correlates of LTR-driven latency potential 
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2.1 Ethics Statement 
 
This is a sub-study of the project titled “Viral set point and clinical progression in HIV-
1 Subtype C infection: the role of immunological and viral factors during acute and 
early infection”. This study was approved by the University of Cape Town’s Faculty of 
Health Sciences Human Research Ethics Committee (UCT FHS HREC) (reference 
number: 025/2004) and the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (reference number: E013/04). Ethical approval for this sub-study was 
obtained from the UCT FHS HREC (reference number 574/2016). Informed consent 




The LTR (HXB2 positions 9086-9621) was amplified from viral isolates generated from 
39 participants in the CAPRISA 002 cohort(285). Viruses were cultured in peripheral 
blood mononuclear cells (PBMCs) over a median of 25 days (range: 25-58) and the 
LTR was cloned into the pGL4.10 vector (viral culturing and clones were provided by, 
P Selhorst, UCT)(285). A 330bp 3’LTR sequence (HXB2 position 9086-9415), from 
plasma virus from acute infection and 12 months post-infection, was available for 26 
of the participants (provided by D. Chopera, UCT/AHRI)(286). The CAPRISA 002 
cohort recruited women who seroconverted during the CAPRISA 004 1% tenofovir 
microbicide gel trial. This is a cohort of sexually active South African women aged 
between 18 and 40 years recruited as HIV-1 negative in high risk urban and rural 
KwaZulu-Natal. Enrolled women were randomised in equal proportions into two study 
arms, the 1% Tenofovir disoproxil fumarate (TDF) microbicide gel or placebo gel. 
Women were followed up monthly and two HIV rapid tests (Determine HIV 1/2 (Abbott 
Laboratories, IL, USA) and Uni-Gold Recombigen® HIV test (Trinity Biotech, Wicklow, 
Ireland)) were performed at each visit. In cases of possible seroconversion, two 
independent RNA PCR assays were performed(287, 288). The date of infection was 




2.3 Sequence analysis 
 
Sanger sequencing was performed at the Central Analytical Facilities at the University 
of Stellenbosch, South Africa, using the ABI3000 Genetic Analyzer and BigDye 
terminator reagents (Applied Biosystems, CA, USA). Sequences were compiled using 
Sequencher (v5.3) and visualised and aligned in AliView (v1.21). Maximum likelihood 
phylogenetic trees were compiled and pairwise DNA distances calculated in MEGA 7 
and trees were edited in Dendroscope (v3.5.9). Nucleotide differences in cloned 
participant LTR sequences were visualised on a Highlighter plot 
(https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html). 
 
The consensus subtype C LTR used for all alignments, pairwise distance calculations 
and phylogenetic analysis was generated from a curated web alignment of a total of 
373 subtype C LTR sequences (HXB2 position 1-532, up to and including sequences 
from 2016), obtained from the Los Alamos National Laboratories Sequence Database 
(http://www.hiv.lanl.gov/), using Consensus Maker tool 
(https://www.hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html). 
 
To confirm the subtypes of our selected participant derived virus panel, a maximum 
likelihood phylogenetic tree was generated from a nucleotide alignment of the 26 
participant derived LTR sequences, 50 subtype C South African and each subtype (A 
through G), consensus LTR sequences (obtained from the Los Alamos National 
Laboratories HIV Sequence Database). To confirm that pGL4.10 cloned LTR 
sequences were representative of plasma derived viruses, another maximum 
likelihood phylogenetic tree was generated from an alignment where the pGL4.10 
cloned sequence was aligned with the acute plasma sequences and 12 months post-




2.4 Gel electrophoresis 
 
DNA fragments were visualised using agarose gel electrophoresis (1% w/v). Agarose 
gels were made up with 1X Tris-Borate-EDTA (TBE) buffer (Appendix 1). 6X Loading 
dye (Thermo Scientific, MA, USA) containing GelRed™ (Biotium, CA, USA) was 
added to all DNA samples to a 1X final concentration before electrophoresis. 
GelRed™ allows for the visualisation of DNA molecules on an agarose gel as it is an 
intercalating agent that interacts with DNA and fluoresces upon exposure to ultraviolet 
(UV) light. Electrophoresis was performed at 100V for between 60 and 75 minutes. 
Gels were visualised under UV light using a Gel Doc™ XR+ Gel Documentation 
System (Bio-Rad, CA, USA). 
 
2.5 pRGH reporter vector 
 
The following reagents were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: pRGH-WT (#12427) and pRGH-ΔU3 (3') (#12430) from 
Ivan Sadowski and Viviana Simon(156, 257–259, 289–293). These constructs were 
used to determine latency potential and for the generation of flow cytometry 
compensation controls (sections 2.6, 2.9, 2.10 and 2.11). 
 
2.6 Construction of Flow cytometry compensation controls 
 
The emission spectra of mCherry and eGFP overlap. Flow cytometry compensation 
controls were constructed expressing only mCherry or eGFP to correct for false 
positive detection of either fluorescent protein during flow cytometric analysis (Figure 
A2.1, Appendix 2). 
 
2.6.1 Construction of an eGFP only reporter plasmid 
 
To generate the eGFP only expressing pseudovirus, the CMV promoter and mCherry 
gene were deleted from the parent plasmid [pRGH (LAI-gagiGFP-CMV-mCherry-
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deltaEnv)] by restriction enzyme digestion. The Thermo Scientific FastDigest 
restriction enzyme kit (Thermo Scientific) was used following the manufacturer 
protocol with these modifications: a total of 3µg of the pRGH plasmid in a final volume 
of 20µl was double-digested with 30 units each of FastDigest BlpI and XhoI restriction 
enzymes (Thermo Scientific) for 2 hours at 37˚C. The total volume of digested 
products was visualised by agarose gel electrophoresis (section 2.4) and the larger 
DNA fragment was excised and purified using the QIAquick Gel Extraction Kit 
(QIAGEN, Hilden, Germany) following the manufacturer protocol. 
 
A blunting reaction was performed on the isolated DNA to remove the incompatible 
extended sticky ends/overhangs, such that blunt end self-ligation of the plasmid was 
possible. The Thermo Scientific CloneJET PCR Cloning Kit (Thermo Scientific) was 
used following the manufacturer protocol with these modifications: 625ng of digested 
linear DNA product in a total volume of 20µl with 10 units of DNA blunting enzyme. 
The blunting reaction was set up on ice followed by incubation at 70˚C for 5 minutes. 
The DNA Blunting Enzyme is a thermostable DNA polymerase with proofreading 
activity, capable of removing 3' overhangs and filling in 5' overhangs to produce 
dsDNA ends. 
 
The blunt-ended linear plasmid was then self-circularized using the Thermo Scientific 
T4 DNA Ligase Self Circularization of Linear DNA Kit (Thermo Scientific) following the 
manufacturer protocol with these modifications: 100ng of blunted linear DNA was 
added to the ligation reaction mixture, 50% (w/v) polyethylene glycol (PEG 4000) 
solution was added to the ligation reaction mixture at a final volume of 5% (w/v) and 
the final volume of the ligation reaction mixture was 20µl. PEG 4000 greatly increases 
the efficiency of the ligation reaction. The mixture was incubated overnight at 16˚C. A 
volume of 5µl of the ligation mixture was subsequently used to transform E. coli XL10-
Gold® Ultracompetent Cells (Agilent Technologies, CA, USA). These are cells 
optimised for transformation of large DNA molecules with high efficiency. The XL10-
Gold® Ultracompetent Cells Transformation manufacturer protocol was followed with 
these modifications: 50µl of competent cell mixture was used, 2µl of the b-
mercaptoethanol (b-ME) mix was added to the cells prior to DNA addition, 200µl of 
Super Optimal broth with Catabolite repression (SOC) was added to the 
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transformation mix post heat-pulse. The total transformation mix was plated on Luria-
Bertani (LB) agar plates containing carbenicillin at a final volume of 100µg/ml 
(Appendix 1) and incubated overnight at 32˚C (Appendix 2).  
 
Bacterial colonies were then screened using Super-Therm Taq polymerase (JMR 
Holdings, London, UK) according to manufacturer instructions to identify clones 
lacking the CMV promoter and mCherry gene. Primers were designed to the nef gene 
and a region within the RGH plasmid downstream of the 3’LTR. Specifically, the Nef 
F forward and pRGH Colony RP reverse primers were used (Table A2.1, Appendix 2). 
The final concentrations of PCR reagents per reaction were as follows: 1X Super-
Therm buffer, 0.015U/µl Super-Therm Taq Polymerase, 2mM magnesium chloride 
(MgCl2), 160µM each dNTPs and 0.15µM of each primer. The following thermal 
cycling conditions were used; 94˚C for 3 min followed by 45 cycles of 94˚C for 30s, 
60˚C for 45s and 72˚C for 2 min, followed by a final elongation step at 72˚C for 10 min. 
The PCR products were analysed by agarose gel electrophoresis (section 2.4). 
Colonies from which the correct DNA fragment was amplified were inoculated in 4ml 
of LB broth (Appendix 1) and incubated at 32˚C overnight (Appendix 2). Plasmid DNA 
was isolated from overnight cultures using the QIAprep® Spin Miniprep Kit (QIAGEN) 
following the manufacturer protocol. 
 
To confirm deletion of the CMV and mCherry genes, 500ng of the plasmid DNA was 
restriction digested with 5 units of FastDigest KpnI (Thermo Scientific) for 1 hour at 
37˚C following the Thermo Scientific FastDigest manufacturer restriction enzyme 
protocol. Digested products were analysed by agarose gel electrophoresis (section 
2.4), clones from samples with correct sized bands of 7300bp, 4830bp and 330bp 
were sequenced. Plasmid DNA was Sanger sequenced (section 2.3) using the Nef F 
forward and pRGH Colony RP (Table A2.1, Appendix 2). Clones with successful 
deletion were designated as pRGH-∆CMV/∆mCherry. 
 
2.6.2 Construction of an mCherry-only reporter plasmid 
 
To generate the mCherry-only expressing pseudovirus, the eGFP gene was removed 
from the parent plasmid (pRGH (LAI-gagiGFP-CMV-mCherry-deltaEnv)) by inverse 
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PCR, using the Phusion High-Fidelity PCR Kit (New England Biolabs, MA, USA) 
following the manufacturer protocol. Phusion is an artificially constructed thermostable 
polymerase with the Pfu DNA polymerase fused to the Sso7d DNA binding domain, 
resulting in an enzyme with extremely high fidelity(294). This polymerase was 
therefore used to minimise the introduction of nucleotide mismatches during the PCR 
reaction. The ^eGFP-pRGH-FP forward and ^eGFP-pRGH-InvPCR(R) reverse 
primers were designed to the start of the p24 and end of p17 regions of the gag gene 
(Table A2.1, Appendix A2), respectively. The final concentrations of PCR reagents per 
reaction were as follows: 1X Phusion HF buffer, 0.02U/µl Phusion High-Fidelity 
Polymerase, 200µM each dNTPs and 0.2µM of each primer. The following thermal 
cycling conditions were used; 98˚C for 2 min followed by 35 cycles of 98˚C for 10s, 
67˚C for 50s and 72˚C for 8 min, followed by a final elongation step at 72˚C for 10 min. 
 
The Thermo Scientific FastDigest manufacturer restriction enzyme protocol was 
followed. The total volume of PCR product (50µl) was digested with 20 units of 
FastDigest DpnI (Thermo Scientific), a restriction enzyme that fragments methylated 
DNA resulting in removal of residual template DNA. Digestion reaction was incubated 
at 37˚C for 2 hours. The DpnI digested product was then self-circularized using the 
Thermo Scientific T4 DNA Ligase Self Circularization of Linear DNA Kit following the 
manufacturer protocol with the following modifications: 5µl of DpnI digested DNA was 
added to the ligation reaction mixture, PEG 4000 Solution was added to the ligation 
reaction mixture at a final volume of 5% (w/v) and the final volume of the ligation 
reaction mixture was 50µl. The ligation reaction mixture was incubated overnight at 
16˚C. A volume of 5µl of the ligation mix was used to transform XL10-Gold® 
Ultracompetent Cells (section 2.6.1). 
 
Bacterial colonies were screened for clones lacking the eGFP gene by PCR 
amplification of DNA in colonies following the Supertherm Taq polymerase protocol. 
Primers were designed to the p24 and p17 regions of gag. The GF-40 forward and 
Gag-BR reverse primers were used (Table A2.1, Appendix 2). Cycling conditions, 
colony PCR screening, plasmid DNA isolation protocols and gel electrophoresis used 
were as described (sections 2.4 and 2.6.1). 
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To confirm deletion of the eGFP gene, 500ng of the plasmid DNA was restriction 
digested with 5 units of FastDigest HindIII (Thermo Scientific) for 1 hour at 37˚C 
following the Thermo Scientific FastDigest manufacturer restriction enzyme protocol. 
Digested products were analysed by agarose gel electrophoresis (section 2.4), clones 
from samples with correct sized bands of 6470bp, 2620bp, 1450bp and 1210bp were 
sequenced. Plasmid DNA were Sanger sequenced (section 2.3) using the gagD-F, 
GF-40 and GF-80 forward and the gagB-R and gagD-R reverse primers (Table A2.1, 
Appendix 2). Clones with successful deletion were designated as pRGH-∆eGFP. 
2.7 Cloning of participant-specific LTRs 
 
Previously, a panel of isolate-derived patient-specific LTR sequences were each 
cloned into the pGL4.10 vector (Figure A2.2, Appendix 2) (provided by, P. Selhorst, 
UCT). pGL4.10 is a promoterless vector with a multiple cloning site upstream of a 
luciferase reporter gene to allow for cloning and measurement of activity of a promoter 
of choice. 
 
Participant LTR sequences were amplified from the pGL4.10 plasmid panel following 
the Phusion High-Fidelity PCR Kit protocol. The pRGH_LTR_F forward and 
pRGH_LTR_R reverse primers (Table A2.1, Appendix A2) were designed to the nef 
gene region 50bp upstream of the start of the U3 region of the LTR and the U5 region 
of the LTR respectively, such that the amplicon included the entire U3 and R region of 
the LTR. The resulting ~650bp PCR product included HIV-1 viral sequence from HXB2 
position 9014 to 9621. Final concentrations of reagents were as described in section 
2.6.2. The following thermal cycling conditions were used; 98˚C for 30s followed by 35 
cycles of 98˚C for 10s, 60˚C for 30s and 72˚C for 5 min, followed by a final elongation 
step at 72˚C for 5 min. 
 
The PCR products were purified following the QIAquick PCR Purification Kit Protocol 
(QIAGEN). To remove the unnecessary flanking sequence, 500ng of purified DNA 
samples were simultaneously digested with 5 units each of the FastDigest XhoI and 
HindIII restriction enzymes, following the Thermo Scientific FastDigest manufacturer 
restriction enzyme protocol. Digested products were purified, following the QIAquick 
PCR Purification Kit Protocol, in preparation for cloning into the RGH-∆U3 vector 
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(Figure A2.3, Appendix 2). This version of the plasmid was chosen for cloning as the 
participant LTR sequences to be cloned mostly comprised of this U3 region. Therefore, 
this deletion prevented interference or potential recombination between the existing 
U3 and the sequence to be cloned. 
 
Due to the lack of unique restriction sites at the cloning site in the pRGH-∆U3 plasmid, 
traditional restriction enzyme (sticky-end) cloning was not possible. Therefore, an 
adaption of restriction-free (RF) cloning was performed (Figure 2.1). RF-cloning is a 
PCR-based method designed to introduce a DNA region of interest into a circular DNA 
vector without restriction digestion or ligation. Canonically, primers are designed to 
add additional base pairs to the DNA sequence to be cloned that are complimentary 
to regions of the target plasmid. This is accomplished by a standard PCR reaction. 
This sequence with added base pairs is then used in a secondary PCR reaction as a 
“mega-primer” which binds to the target plasmid “template” via complimentary 
sequences. The double stranded DNA sequence to be cloned becomes single 
stranded during denaturation and the complimentary regions anneal to the target 
plasmid on both ends with the sequence to be cloned behaving as an overhanging 
loop. Double stranded DNA is generated from both annealed ends and the sequence 
to be cloned is incorporated as the PCR is completed(295, 296). However, when 
cloning participant LTRs into the pRGH-∆U3 plasmid complimentary regions to 
approximately 90bp of the nef region and 80bp of R region of the LTR were present in 
the 650bp amplicon described above, therefore addition of excess complimentary 




Figure 2.1 Schematic representation of the RF-cloning reaction. Primers were designed to 
regions flanking the U3 and R regions of the LTR which had previously been cloned into the 
pGL4.10 vector. During a first round PCR the LTR is amplified out of the pGL4.10 plasmid to create 
a ”mega-primer”. This “mega-primer” is used in a secondary PCR reaction where the 5’ and 3’ 
ends of the amplicon hybridise to the corresponding regions flanking the U3 and R regions of the 
LTR, which are also present in the pRGH-∆U3 plasmid acting as the DNA template. Replication is 
initiated from each end of the primer and the entire pRGH-∆U3 plasmid is replicated incorporating 
the mega-primer into the sequence. PCR amplification results in production of a double nicked 
circular double-stranded DNA molecule. DpnI digestion is performed on the secondary PCR to 
selectively remove parental template pRGH-∆U3 DNA leaving the nicked dsDNA molecule with 
the LTR of interest incorporated intact. 
 
A total of three condition sets were used to attempt the RF-cloning procedure with the 
Phusion High-Fidelity PCR Kit. Initially, a total of 125ng of patient-specific LTR “mega-
primer” and 10ng of the pRGH-∆U3 “template” was added to the reaction in a final 
volume of 50µl. The final concentrations of PCR reagents per reaction were as follows: 
1X Phusion HF buffer, 0.02U/µl Phusion High-Fidelity Polymerase, 200µM each 
dNTPs. The following thermal cycling conditions were used; 98˚C for 2 min followed 
by 18 cycles of 98˚C for 10s, 60˚C for 30s and 72˚C for 8 min, followed by a final 
elongation step at 72˚C for 5 min. The total volume of PCR product (50µl) was digested 
with DpnI as described in section 2.6.2, however 10 units of enzyme were used and 
the reaction was incubated for 1 hour. 
 
Secondly, we reduced the recommended amount of plasmid template DNA to 50ng 








respectively, and finally, the total volume of PCR product (50µl) was digested with 
DpnI (section 2.6.2) with 20 units of enzyme per reaction for 2 hours. Other reaction 
conditions remained the same as described above. 
 
A volume of 5µl of the RF-cloning product was used to transform XL-10 Gold Ultra-
Competent Cells (section 2.6.1). Bacterial colonies were screened for inserts by 
colony PCR. PCR amplification of DNA in colonies was performed following the 
Supertherm Taq polymerase protocol. The pRGH_LTR_FP forward and pRGH Colony 
RP reverse primers (Table 2A.1, Appendix 2) were designed to the nef gene and a 
region within the plasmid downstream of the 3’LTR, respectively. Cycling conditions, 
colony PCR screening, plasmid DNA isolation and gel electrophoresis protocols used 
were as described (section 2.4 and 2.6.1). To confirm insertion of the participant LTR 
500ng of the plasmid DNA was restriction digested with 5 units of FastDigest HindIII 
for 1 hour at 37˚C following the Thermo Scientific FastDigest manufacturer restriction 
enzyme protocol. Digested products were analysed by agarose gel electrophoresis 
(section 2.4). A schematic of the bacterial transformation and clone screening 




Figure 2.2 Screening for clones with participant LTRs incorporated into the pRGH-∆U3 
plasmid after RF-cloning. The intact nicked dsDNA molecule with the LTR of interest 
incorporated is subsequently transformed into competent bacteria and plated on LB agar 
containing carbenicillin and incubated at 32˚C overnight. Bacterial colonies were inoculated directly 
into PCR master mixes and also into LB broth containing carbenicillin and incubated at 32˚C 
overnight. PCR reactions were run with primers flanking the target site of interest and products run 
on an agarose gel to screen clones for the presence of a correctly sized DNA insert (LTR). Plasmid 
DNA was extracted the overnight cultures, digested with HindIII and run on an agarose gel to 
screen for clones. Figure elements adapted from the QIAGEN QIAprep® Miniprep Handbook 
obtained at: https://www.qiagen.com/us/resources/resourcedetail. 
 
Successful clones were confirmed by Sanger sequencing (section 2.3) using the 
pRGH_LTR_F forward and pRGH Colony RP reverse primers (Table 2A.1, Appendix 
2). 
 
2.8 Cell Culture 
 
2.8.1 Adherent cell lines 
 
Two adherent cells lines were used. The HEK293T cell line, isolated from human 
embryonic kidney cell line is highly transfectable and capable of producing high titre 
retroviruses from retrovirus vector DNA (American Type Culture Collection ATCC® 
CRL3216™).The following reagent was obtained through the NIH AIDS Reagent 
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Wu and Tranzyme Inc(297–301). The TZM-bl cell line which is a HeLa cell line 
derivative, is an immortalized cell line derived from cervical cancer cells that expresses 
the CD4 and CCR5 cell surface receptors necessary for HIV-1 viral entry(302).  
 
TZM-bl cells have also been stably transfected with a reporter plasmid harbouring the 
Firefly luciferase gene under the control of a Tat inducible HIV-1 LTR promoter. After 
entry, reverse transcription, integration and protein expression from HIV-1 
viruses/pseudoviruses in the TZM-bl cell line, the Tat protein binds to the LTR in the 
reporter system resulting in the expression of luciferase. Measurement of this 
luciferase by the addition of a luciferin containing reagent (Bright-GloTM, Promega, WI, 
USA) to the infected cells, allows for the quantification of viral infectivity via 
measurement of chemiluminescence. Bright-GloTM reagent facilitates the lysis of the 
TZM-bl cells and contains beetle luciferin, the substrate for Firefly luciferase which is 




Figure 2.3 Schematic of the bioluminescent reaction catalysed by Firefly luciferase. Figure 




Both cell lines were maintained at 37˚C in 5% CO2 (v/v) (hereinafter referred to as 
standard incubation conditions), in complete Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Thermo 
Scientific), 50µg/ml gentamicin antibiotic (Lonza). This media was referred to as D10+. 
Cells were grown in a humidified incubator in T75 filter-cap tissue culture flasks and 
passaged approximately every 3 days or when cell confluency exceeded 80%. A 
number of studies have shown that passaging cells many times can lead to changes 
in cell morphology, growth characteristics, protein expression and may negatively 
affect transfection efficiency. Therefore, cells were not used after passage 30 and 
were instead discarded. 
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HEK293T cells were passaged as follows: Media was removed from the culture flask 
leaving the cell monolayer intact. Cells were washed with 8ml 1X Dulbecco’s 
Phosphate-Buffered Saline (DPBS) lacking calcium (Ca2+) and magnesium (Mg2+) 
ions as these inhibit Trypsin enzymatic function and are contained within D10+ media. 
Trypsin is a serine protease, which cleaves peptide chains at the C-termini of lysine 
or arginine amino acid residues, which are responsible for cell adhesion to the culture 
flask. Ethylenediaminetetraacetic acid (EDTA) is a chelating agent of divalent cations 
and therefore enhances Trypsin efficiency. A volume of 1ml of 1X Trypsin-EDTA 
(0.25% Trypsin, EDTA 1mM) was added to the flask and incubated for 1 minute at 
room temperature. 10ml of D10+ was then added to the flask to inactivate the trypsin 
and resuspend cells. To count and determine percentage viability of cells, a 0.4% 
Trypan Blue Stain (Invitrogen, CA, USA) was performed. This is an azo dye and works 
on the principle that dead cells have compromised cell membranes and therefore take 
up the dye whereas live cells with intact membranes do not. The staining procedure 
was performed as follows: A 1:2 dilution of cells was made with Trypan Blue, 10µl of 
this mixture was added to a Countess cell counting chamber (Invitrogen) slide and cell 
count was determined using a Countess automated cell counter. A total of 5 x 105 to 
1 x 106 cells were seeded into each new flask in a final volume of 12ml of D10+ media.  
 
TZM-bl cells were passaged following the same procedure with the following 
exception; 3ml of Trypsin-EDTA was added to the flask after the monolayer was 
washed with 1X DPBS. Cells were then incubated for 1 minute at room temperature 
after which 1ml of Trypsin-EDTA was removed from the flask. The flask was then 
incubated at 37˚C for an additional 5 minutes before the addition of D10+ media. 
Addition of media inactivates the activity of the trypsin. 
 
2.8.2 Suspension cell lines 
 
The following reagent was obtained through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH: Jurkat Clone E6-1 from Dr. Arthur Weiss. The Jurkat cell line is 
an immortalized cell line established from the peripheral blood of a 14-year-old patient 
with T cell leukaemia. The specific Jurkat E6-1 clone utilised in this study is a CD4+ 
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suspension T cell line which expresses high levels of IL-2 upon stimulation with both 
phorbol esters and either monoclonal antibodies against to the T3 antigen or 
lectins(303).  
 
The following reagent was obtained through the NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH: CEM.NKR CCR5+ Cells from Dr. Alexandra Trkola(304–306). 
The CEM.NKR CCR5+ cell line is a Human T-lymphoblastoid cell line that is a CEM 
CD4+ suspension cell line variant resistant to natural killer (NK) cell killing. 
 
Jurkat E6-1 and CEM.NKR CCR5+ cells were maintained under standard incubation 
conditions, in complete Roswell Park Memorial Institute (RPMI-1640) (Lonza, Basel, 
Switzerland) media supplemented with 10% heat-inactivated FBS (Thermo Scientific) 
and 50µg/ml gentamicin antibiotic. This media was referred to as R10+. 
 
Jurkat E6-1 and CEM.NKR CCR5+ cells were passaged as follows: Media containing 
cells was removed from the culture flask, transferred to a 15ml conical flask and 
centrifuged at 887 x g for 8 minutes at room temperature. The supernatant was 
subsequently discarded and the cell pellet was resuspended in 4ml of R10+ media. 
Cells were counted as described for the HEK293T cell line. An aliquot of the 
resuspended cells was then seeded into a new T25 cell culture flask at a concentration 
of 2.5 x 105 live cells/ml of R10+ media in a total volume of 8ml. This procedure was 
carried out every 72-96 hours or when cell confluency exceeded 3 x 106 cells/ml. 
 
2.9 Generation of pseudovirus stocks 
 
To produce the RGH pseudoviruses, HEK293T cells were co-transfected with the 
pHEF-VSVg envelope protein expressing plasmid and each pRGH LTR clone or one 
of the pRGH-WT, pRGH-∆eGFP and pRGH-∆CMV/∆mCherry plasmids. The 
Lipofectamine 3000 (Thermo Scientific) transfection reagent was used for transfection 
of the cells. Lipofectamine 3000 is a positively charged cationic lipid that interacts with 
the phosphate backbone of DNA molecules mediating interaction of the DNA and the 
cell membrane of target cells. The Lipofectamine/DNA complex therefore fuses with 
the negatively charged cell membrane facilitating entry via endocytosis(307–309). 
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This transfection reagent allows for high transfection efficiency, with multiple plasmids, 
and induces minimal cell death. 
 
For each clone, 8µg of the pRGH plasmid and 2µg of the pHEF-VSVg plasmid (4:1) 
was mixed with 5µl of the P3000 Reagent and 12µl of Opti-MEMTM-Reduced Serum 
Media (Gibco®, Thermo Scientific) in a 15ml conical tube. Opti-MEM™ is used as it 
maintains a more consistent pH when compared to D10+ and serum in media reduces 
transfection efficiency(310). A volume of 5µl of the Lipofectamine 3000 Reagent and 
125µl of Opti-MEM™ was mixed in a separate 15ml conical tube. 
 
The Lipofectamine mixture was then added to the plasmid mixture, mixed by vortexing 
and incubated at room temperature for 15 minutes to allow for Lipofectamine/DNA 
complexes to form. During incubation, HEK293T cells were seeded at 1.2 x 106/well 
in a 6-well plate in a total volume of 1ml of D10+ media. The Lipofectamine/plasmid 
mixtures were then directly added to separate wells and each well made up to a final 
volume of 2ml by the addition of D10+ media. Plates were incubated for 48 hours 
under standard incubation conditions. Pseudovirus stocks were harvested by 
centrifugation of culture medium at 887 x g for 8 minutes to remove cells/cell debris. 
200µl aliquots of the pseudovirus containing supernatant were transferred to cryovials 
and stored at -80˚C. 
 
Each pseudovirus underwent titration in three different cell lines to confirm functionality 
and the necessary viral volume for infection. 
 
2.9.1 TZM-bl titration 
 
Pseudovirus stocks were titrated on TZM-bl cells to evaluate/screen for functionality. 
A 50% Tissue Culture Infectious Dose (TCID50) assay was performed to measure the 
amount of virus required to produce a cytopathic effect (CPE) in 50% of TZM-bl cells 
inoculated with serially diluted viral stocks. Each viral stock underwent a 1:5 serial 
dilution in D10+ media containing Diethylaminoethyl (DEAE)-dextran at a 
concentration of 40µg/ml. DEAE-dextran is a polycation that stabilises viral adsorption 
to the cell membrane of TZM-bl cells thereby promoting cell-free viral uptake. Dilutions 
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were performed in duplicate over the first seven wells in a 96-well tissue culture 
microtiter plate in a final volume of 100µl. Eight background control wells were included 
per plate (eighth row) containing only 100µl of D10+ media with no virus. TZM-bl cells 
were then seeded into to each well at 1x104 cells in 100µl of D10+ such that the final 
volume in each well containing cells and virus was 200µl with a final DEAE-dextran 
concentration of 20µg/ml. 
 
Following a 48-hour incubation under standard incubation conditions approximately 
80µl (to account for evaporation) of supernatant was removed from each well such 
that 100µl of cells/media/virus remained. 100µl of BrightGlo reagent (Promega) was 
added and the plate was incubated at room temperature in the dark for 2 minutes. The 
contents of each well were thoroughly mixed by pipette action and 150µl were 
transferred to an opaque black 96-well microtiter plate. Luminescence readings were 
then acquired as relative light units (RLU) in a GLOMAX® 96-Microplate Luminometer 
using the Promega BrightGlo™ Protocol; Promega, WI, USA. Viral titres (infectious 
units of virus per ml) were calculated following the Reed-Muench method(311). 
 
2.9.2 Jurkat E6-1 & CEM.NKR CCR5+ Titration 
 
It was recommended that 10-20% eGFP expression one day post infection should 
yield infection with only single viral integrations within cells (Marcel Ooms, personal 
communication). To determine the necessary volume required to infect cells such that 
10-20% of cells expressed eGFP one day post-infection, Jurkat E6-1 or CEM.NKR 
CCR5+ cells were infected with two titres of each viral stock. A total of 1.0 x 106 Jurkat 
E6-1 cells per well in a 6-well tissue culture plate were infected with either 50µl or 
150µl of each viral supernatant, in a final volume of 2ml of D10+ media supplemented 
with 4µg/ml Polybrene. Polybrene is a cationic polymer which increases viral infection 
by enhancing adsorption of virus to target cells membranes in a receptor independent 
manner(312). Cells were then subjected to spinoculation at 500 x g for 90 minutes at 
room temperature. Plates were finally incubated for 24 hours under standard 
incubation conditions.  
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A total of 5.0 x 105 CEM.NKR CCR5+ cells per well in a 12-well tissue culture plate 
were infected with either 100µl or 250µl of each viral supernatant, in a final volume of 
2ml of D10+ media supplemented with 4µg/ml Polybrene. Cells were then subjected 
to spinoculation at 1000 x g for 90 minutes at room temperature. Plates were finally 
incubated for 24 hours under standard incubation conditions. 
 
For both cell lines eGFP expression on day one post-infection at different viral volumes 
was used to extrapolate the approximate viral titre required to obtain 10-20% eGFP 
expression assuming a linear relationship between viral titre and eGFP expression. 
 
2.9.3 Confirmation of 5’LTR replacement 
 
To confirm that the LTR cloned into the 3’LTR position of pRGH was successfully 
regenerated at the 5’LTR position upstream of the gag-eGFP cassette, the 5’LTR was 
amplified and sequenced from the integrated proviral within genomic DNA of cells 
infected with each pseudovirus. Jurkat E6-1 cells were infected as described in section 
2.9.2, however to increase the frequency of integration events without inducing high 
levels of cell death, a volume of pseudovirus that yielded approximately 50% eGFP 
expression one day post-infection (based on data obtained from experiments in 
section 2.9.2) was used. Cells were maintained under standard incubation conditions 
over a period of 4 days to allow for integration to take place. A volume of 500µl of 
culture media was removed and replaced with fresh media after 48 hours. On day 4 
post-infection, genomic DNA was extracted from infected cells using the QIAamp
 
DNA 
Mini and Blood Mini Kit, following the DNA Purification from Blood or Body Fluids Spin 
Protocol. DNA was extracted from a total of approximately 4 x 106 Jurkat E6-1 cells 
and purified DNA was eluted in 50µl of AE buffer. 
 
The integrated proviral 5’LTR sequence was amplified from purified genomic DNA via 
PCR following the Phusion High-Fidelity PCR Kit protocol. Primers were designed to 
a region complimentary to the start of the LTR and to the matrix region of gag. The 
cLTR_F forward and SQ16RC reverse primers were used (Table A2.1, Appendix 2). 
Final concentrations of reagents were as described in section 2.6.2. The following 
thermal cycling conditions were used; 98˚C for 2 min followed by 35 cycles of 98˚C for 
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30 sec, 62˚C for 30 sec and 72˚C for 30 min, followed by a final elongation step at 
72˚C for 10 min. The PCR products were run on an agarose gel as described in section 
2.4. Amplicons identified as approximately 1010bp in size, corresponding to the 
amplified proviral LTR, were excised from the gel and purified following the QIAquick 
Gel Extraction Kit Protocol. The purified DNA amplicon was Sanger sequenced 
(section 2.3) using the cLTR_F forward and SQ16RC reverse primers (Table A2.1, 
Appendix 2). 
 
2.10 eGFP profile over time 
 
To determine which day post-infection fluorescent protein expression stabilised and 
latency potential should be measured most accurately, cells were infected with pRGH 
pseudovirus and eGFP expression was measured over time. Jurkat E6-1 cells were 
infected (section 2.9.2) with the pRGH-WT pseudovirus at viral supernatant volumes 
ranging from 0-1000µl. eGFP expression was measured one, two, three, four, seven 
and eight days post-infection for each sample where 500µl of culture was prepared for 
flow cytometric analysis (section 2.11.3) on each day post-infection with replacement 
of 500µl of R10+ media. CEM.NKR CCR5+ cells were also infected (section 2.9.2) with 
three participant LTR-pseudotyped RGH viruses and eGFP expression was measured 
for each infection over a six-day period where 500µl of culture was prepared for flow 
cytometric analysis (section 2.11.3) on each day post-infection with replacement of 
500µl of R10+ media. 
 
2.11 Measurement of Latency Potential 
 
2.11.1 LTR panel infection 
 
Jurkat E6-1 cells were infected with each pseudovirus to result in 10-20% of cells 
expressing eGFP on day one post-infection (section 2.9.2). Cells were maintained in 
culture under standard incubation conditions over an eight-day period where 1ml of 
culture media was removed and replaced with fresh media every other day until day 
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six post infection. On day seven post infection, each infected cell culture sample was 
divided equally into two subsets and transferred to new 6-well culture plates. One 
subset was treated with phorbol 12-myristate 13-acetate (PMA) and Ionomycin (Iono) 
at final concentrations of 4ng/ml and 1µM dissolved in Dimethyl sulfoxide (DMSO), 
respectively (stimulated). The other subset was treated with the equivalent volume of 
DMSO (unstimulated). PMA and Iono are compounds capable of inducing T cell 
activation via the activation of the PKC cascade. All wells for both subsets were made 
up to a final volume of 2ml. On day eight, all samples underwent flow cytometric 
analysis (section 2.11.1). This eight-day assay was performed in triplicate on three 
separate occasions. 
 
CEM.NKR CCR5+ cells were infected as previously described (section 2.9.2). Cells 
were maintained as above, however, 500µl of culture media was removed and 
replaced every second day, and on day seven post infection cell culture samples were 
divided and transferred to 12-well culture plates and all wells were made up to 1ml 
after addition of treatment compounds. This assay was performed in triplicate on three 
separate occasions. 
 
2.11.2 Compensation control pseudovirus infections 
 
Jurkat E6-1 and CEM.NKR CCR5+ cells were infected with each compensation control 
pseudovirus (section 2.9.2), pRGH-∆CMV/∆mCherry and pRGH-∆eGFP, one and four 
days prior to flow cytometric acquisition of each latency potential assay (section 2.11), 
respectively. Cells were maintained in culture under standard incubation conditions. 
For the pRGH-∆eGFP pseudovirus infected cells, 1ml or 500µl of culture media was 
removed and replaced with fresh media on day two post-infection for Jurkat E6-1 and 
CEM.NKR CCR5+ cells, respectively. On day three post-infection, pRGH-∆eGFP 
pseudovirus infected cells were treated with PMA/Iono (section 2.11) to stimulate high 
levels of expression of mCherry. On the corresponding day eight of each latency 
potential assay, these samples also underwent flow cytometric analysis. 
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2.11.3 Flow Cytometry Acquisition and Analysis 
 
On the selected day post-infection, infected Jurkat-E6 and CEM.NKR CCR5+ cells 
were pelleted by centrifugation at 887 x g for 8 minutes at room temperature and 
resuspended in 1% (v/v) paraformaldehyde and incubated at room temperature for 10 
minutes to allow cell fixation prior to flow cytometric acquisition. 
 
Flow cytometric data for this project was acquired on either a Becton Dickinson (BD) 
FACSCalibur™ using BD CellQuest™ Pro software for the GFP titrations or a BD 
LSRFortessa™ using FACSDIVA™ software for all other data acquisition. Data was 
analysed on FlowJo version 10.2 (Treestar Inc.) 
 
2.11.4 Gating strategy 
 
For all samples run on the FACSCalibur™, a total of 40 000 live events were recorded. 
Dead cells were excluded as determined by the forward scatter area vs. side scatter 
area profiles [FSC-A/SSC-A] of the cells. Cells were then gated on eGFP expression 
based on uninfected cell populations (Figure 2.4). 
 
 
Figure 2.4 Gating strategy to identify the population of eGFP expressing cells. Gates are 
based on uninfected Jurkat E6-1 cells. Cells were gated on A) Live Cells and B) eGFP expression. 
 
For all samples run on the LSRFortessa™, a total of 100 000 total events were 











intensity during the acquisition run. Dead cells were then excluded as determined by 
the forward scatter area vs. side scatter area profiles [FSC-A/SSC-A] of the cells. 
Doublet events were excluded as determined by the forward scatter area vs. forward 
scatter height profiles [FSC-A/FSC-H] of the cells. Finally, cells were gated for single 
or co-expression of eGFP and mCherry expression based on uninfected cell 
populations (Figure 2.5). 
 
 
Figure 2.5 Gating strategy to identify populations of mCherry and eGFP expressing cells. 
Uninfected Jurkat E6-1 cells treated with DMSO for 24 hours. Cells were gated on Time A), Live 
Cells B), Singlet events C) and finally mCherry and eGFP expression D) 
 
Latency potential was defined as the ratio of latently infected cells to actively infected 
cells and was thus calculated as follows: 
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2.12 Measurement of LTR activity 
 
The panel of LTR cloned pGL4.10 plasmids described in section 2.7 was used to 
measure the basal and Tat-induced expression of each participant LTR for which 
latency potential had been determined in section 2.11. 
 
HEK293T cells were co-transfected with 100ng of the each of the pGL4.10 LTR 
plasmids, 25ng of the pRL-SV40 vector and a range of concentrations of the 
pcDNA™3.1/V5-His-TOPO vector, with the CAP063 tat gene cloned into the multiple 





















tat sequence was cloned from a subtype C infected participant who is a rapid 
progressor in the CAPRISA 002 cohort(313). 
 
PolyFect transfection reagent (QIAGEN) was used for transfection of these cells. For 
each participant, the pGL4.10, pRL-SV40 and Tat-TOPO vectors were diluted in D10+ 
media, mixed and added to each of the corresponding wells of a 96-well plate. 
PolyFect was added at a concentration of 40µg/ml per well in a total volume of 100µl 
(PolyFect and vector mixes). Plates were incubated at room temperature for 10 
minutes to allow for PolyFect-DNA complexes to form. HEK293T cells were then 
seeded at 2.0 x 104 cells per well, in 100µl of D10+ media, into each well of the 96-
well plate such that each well was made up to 200µl containing PolyFect at a final 
concentration of 20µg/ml. Transfections with a HIV-1 Subtype B BaL LTR sequence 
cloned into the pGL4.10 vector and a pGL4.10 with no LTR cloned in at each Tat-
TOPO concentration were included as normalisation controls. Each transfection 
reaction was set up in triplicate. Plates were incubated for 48 hours under standard 
incubation conditions. 
 
Following incubation, 120µl of supernatant was removed from each well such that 80µl 
of culture media remained. A volume of 75µl of Dual-Glo® Luciferase Assay Reagent 
(Promega), containing beetle luciferin, was added to each well of the plate and the 
plate was incubated at room temperature in the dark for 10 minutes. The contents of 
each well were thoroughly mixed by pipette action and 100µl were transferred to an 
opaque black 96-well microtiter plate. Firefly luminescence readings were then 
obtained as relative light units (RLU) in a GLOMAX® 96-Microplate Luminometer 
using the Promega Dual-Glo Protocol; Promega, WI, USA. A volume of 75µl of Dual-
Glo® Stop & Glo® Reagent (Promega), containing coelenterazine, was added to each 
well of the 96-well plate and the plate was incubated at room temperature in the dark 
for a further 10 minutes. 
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Renilla luminescence readings were then obtained as relative light units (RLU) as 
described above. Transfection efficiency was controlled for by normalising 
luminescence readings against Renilla luciferase expression. Luciferase reactions are 
shown in Figure 2.6. LTR activity was calculated as a response ratio relative to the 
activity of the BaL isolate LTR sequence (provided by P Selhorst, UCT), to provide a 
method to standardise readings and control for inter-experiment variation, and 
expressed as a factor of BaL activity(314). Therefore, LTR activity for each participant 











FLL: Firefly luciferase luminescence 
RLL: Renilla luciferase luminescence 
NC: Negative control (pGL4.10 with no LTR) 
 
Figure 2.6 Bioluminescent reactions catalyzed by Firefly and Renilla luciferases. Beetle 
luciferin undergoes mono-oxygenation, catalyzed by Firefly luciferase, to oxyluciferin and light. 
Coelenterazine undergoes mono-oxygenation, catalyzed by Renilla luciferase, to coelenteramide 




Figure 2. ioluminescent reactions catalyzed by firefly and Renilla luciferases.
Mono-oxygenation of beetle luciferin is catalyzed by firefly luciferase in the
presence of Mg2+, ATP and molecular oxygen. Unlike beetle luciferin, coelenterazine
undergoes mono-oxygenation catalyzed by Renilla luciferase but requires only
molecular oxygen.
Figure 3. Comparison of the signal decay of luciferases in Dual-Glo® Reagent 
and DLR™ Assay Reagent. The two luciferase assay reagents were compared using
1.67 × 10–9M (plus 1mg/ml gelatin) firefly and Renilla luciferase (20µl and 100µl of
enzyme mix were used with DLR™ and Dual-Glo® Reagents, respectively). The
luciferases were diluted in RPMI 1640 before assaying with Dual-Glo® Luciferase
Reagent and in Passive Lysis Buffer (Cat.# E1941) before assaying with DLR™
Assay Reagent. The DLR™ Assay measurements were taken immediately after
reagent addition, while the Dual-Glo® measurements were taken after a 10-minute
incubation at room temperature. Luminescence was integrated over 0.5 seconds 
per well at regular intervals until 2 hours after reagent addition. Panel A. Firefly
luciferase activity in Dual-Glo® and DLR™ Assays. Panel B. Renilla luciferase
activity in Dual-Glo® and DLR™ Assays.
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2.13 Statistical analysis 
 
Graphs were generated and statistical analysis performed in GraphPad Prism 7.0a 
(GraphPad Software, La Jolla California USA, www.graphpad.com). Spearman 
correlation (CI=95%) tests were performed for all correlations due to the small sample 
sizes. Statistical significance was calculated using the Wilcoxon matched-pairs signed 
rank test and a p-value of <0.05 was considered significant. Where multiple 
comparisons were made, a one-way analysis of variance (ANOVA), followed by a 
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This study investigated LTR latency potential and promoter activity of the HIV-1 LTR 
DNA sequence isolated from recently infected participants from the CAPRISA 004 
cohort (estimated duration of infection: median 5 weeks, range 3-12) (acute/early 
infection) (section 2.2)(287). LTR clones and sequences (n=26) (HXB2 positions 
9086-9621) were available from acute/early time points (provided by P. Selhorst, 
UCT), and in addition, a 330bp U3 region sequence (HXB2 position 9086-9415) 
generated directly from plasma virus from acute/early infection and 12 months post-
infection respectively was available for all participants (Chopera et al.)(286). 
 
3.1 Selection of a subtype C LTR panel 
 
To determine whether the LTR sequences were representative of subtype C South 
African viruses, phylogenetic analysis was performed. The 26 acute/early LTR clone 
sequences were compared to 50 subtype C South African sequences and to each 
subtype, A through G, consensus LTR sequence (obtained from the Los Alamos 
National Laboratories HIV Sequence Database http://www.hiv.lanl.gov/) (Figure 3.1). 
The participant LTR sequences clustered exclusively with the subtype C sequences 
and were dispersed amongst South African subtype C sequences. This confirmed that 
they were all subtype C, that there were no recent phylogenetic linkages between 




Figure 3.1 Subtype diversity of the LTR. The evolutionary history was inferred using the 
Maximum Likelihood method based on the Tamura-Nei model(315). The tree is drawn to scale, 
with branch lengths measured in the number of substitutions per site. The panel of 26 selected 
CAPRISA 004 LTR sequences, a selection of 50 South African subtype C sequences and a 
consensus sequence for each subtype was included. Different sequences are identified by 
coloured shapes detailed in the key. A total of 451 nucleotide positions were included in the final 
dataset, covering the U3 and R regions of the LTR. Scale bar (top left of figure) = 0.01. Black stars 
represent nodes at which bootstrap support was ³80. 
 
The LTR clones originated from plasma virus, cultured in PBMCs over a median of 25 
days (range 25-58) (Selhorst et al.)(285). The HIV-1 viral replication cycle takes 
approximately 2 days, and the viral reverse transcriptase enzyme has an inherently 
low fidelity and is prone to introducing mutations during replication(316, 317). There is 
therefore potential for viral evolution during culture. We thus investigated whether the 
cloned LTR sequences represented the in vivo plasma viruses from these women at 
a matched time point using DNA distance analyses. The mean intra-participant 
pairwise DNA distance between the cloned sequence and matched acute plasma virus 
sequence was 0,0036 (range 0-0.032) (Figure 3.2). One participant, CAP352, had a 




Figure 3.2 Scatter plot of pairwise DNA distances between the acute and matched pGL4.10 
cloned matched LTR sequences. The number of base substitutions per site between sequences 
are shown. Analyses were conducted using the Maximum Composite Likelihood model(318). A 
total of 329 nucleotide positions were analysed. The central bar shows the mean and the error 
bars represent the standard deviation of the mean. 
 
Furthermore, to investigate whether the difference between the proviral and plasma 
sequence was greater than we would expect for intra-person variation, we generated 
a maximum likelihood phylogenetic tree to compare cloned LTR and acute/early 
infection sequences to those generated from 12 months post-infection (Figure 3.3). 
Participant sequences grouped together, confirming their identity. Of the 26 
participants: all three sequences from different time points/sources were identical for 
six participants; the cloned sequence was identical to or grouped more closely with 
the acute sequence for 13 participants; and in seven participants there was higher 
diversity between the cloned and acute sequences compared to the acute and 12-
month post-infection sequences. Of the latter seven, cloned sequences were 























Figure 3.3 Phylogenetic tree of CAPRISA 004 LTR sequences. The evolutionary history was 
inferred by using the Maximum Likelihood method based on the Tamura-Nei model(315). The tree 
is drawn to scale, with branch lengths measured in the number of substitutions per site. The 
analysis involved 76 nucleotide sequences. A panel of 26 CAPRISA 004 participants were included 
with sequences obtained during acute infection (at participant enrolment) (blue triangles), at 
chronic infection (at 12 months post-infection) (red circles), and sequences from the panel of 
pGL4.10 cloned LTRs (green squares). There were a total of 322 positions in the final dataset 
including the entire overlapping nef/U3 region of the LTR. The tree was rooted on the global 
Consensus C LTR sequence (purple diamond). Scale bar (top centre of figure) = 0.02. 
 
Participant LTR sequences that were a 100% match or were more similar to the 
corresponding acute plasma sequence than to the 12 months post-infection plasma 
virus sequence were selected for further investigation (n=18). One additional 
participant (CAP360) was included who was identified as being infected by multiple 
transmitted variants of HIV-1(288). Therefore, based on the results above, a total of 
19 participant-derived LTR clones were utilized in further experiments (Table A.1, 
Appendix 3). 
  
Sequence from the pGL4.10 clone





3.2 Generation of a panel of LTR-pseudotyped RGH viruses 
 
The effect of the LTR genotype on viral latency was evaluated using an in vitro model 
where the participant-derived LTRs were cloned into the pRGH-∆U3 vector (Figure 
A2.3, Appendix 2). This plasmid harbours a gag-eGFP gene under the control of the 
LTR and an mCherry gene under the control of a constitutive CMV promoter (see 
section 1.8.2.3). This construct was used to generate chimeric HIV-1 pseudoviruses. 
Following infection, simultaneous detection of eGFP and mCherry was indicative of 
active viral expression, whereas expression of mCherry alone indicated viral 
integration but no HIV-1 expression (latent infection). Therefore, pRGH allowed for the 
simultaneous detection of actively and latently HIV-1 infected CD4+ T cells. 
 
3.2.1 Restriction-Free Cloning Optimisation 
 
To assess the effect of genotypic variation within the panel of subtype C LTRs on the 
ability to establish latency, participant LTRs were cloned into the RGH plasmid. As the 
RGH plasmid lacked unique restriction sites flanking the desired insertion site, an RF-
cloning strategy was implemented. RF-cloning is a PCR-based cloning procedure 
where sequences to be cloned are incorporated during the PCR reaction via flanking 
sequences complimentary to the target plasmid. 
 
Participant LTRs were amplified from the pGL4.10 clone panel and an approximately 
650bp DNA fragment (HXB2 positions 9014-9621) corresponding to the U3, R and 





Figure 3.4 CAPRISA 004 participant LTRs amplified from the pGL4.10 panel. A 1% agarose 
gel of HIV-1 3’LTR including 72bp of pGL4.10 vector upstream of the LTR start site and the entire 
U3 and R region of the LTR producing a band of approximately 650bp. Lane 1: The O’GeneRulerTM 
1 kb DNA Ladder (Thermo Scientific), Lanes 2-13 PCR amplified LTR sequences from participants: 
CAP283, CAP303, CAP306, CAP311, CAP314, CAP315, CAP320, CAP326, CAP343, CAP360, 
CAP367, CAP372 PCR respectively, Lane 14 Negative PCR control (no template DNA added to 
reaction). Electrophoresis was performed for 40 minutes at 100V. DNA was stained with GelRedTM 
and the gel was visualised under UV light. 
 
The LTRs were cloned into the 3’LTR site of pRGH-∆U3 (Figure A2.3, Appendix 2). 
During the viral replication cycle, the 3’LTR is transferred to the 5’ end of the genome 
(see section 1.6.1) to generate the U3 and R region of the 5’LTR upstream of the gag-
eGFP cassette. Due to the size of the target RGH-∆U3 plasmid (approx. 13.5kb), the 
RF-cloning reaction was inefficient. Therefore, a number of conditions were tested in 
order to develop the most efficient cloning protocol possible, which yielded the most 
positive clones following bacterial transformation and colony screening (Table 3.1). Of 
three condition sets tested, condition set 3 was found to yield the highest colony 
positivity rate of between 10-25%. A total of seven different participant LTRs were 
used for this optimization. Increased DpnI and digestion time appeared to reduce the 
number of clones which produced the parent plasmid banding pattern. 
 
1 2 3 4 5 76 8 9 10 11 12 13 14
±650bp
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Table 3.1 Optimsiation of conditions used for RF-cloning. 
 
 
3.2.2 Confirmation of cloning and pseudovirus generation 
 
Three methods were used to confirm insertion of the LTR into the correct position of 
pRGH: (i) DNA amplification, (ii) restriction enzyme mapping and (iii) Sanger 
sequencing. DNA amplification of bacterial colonies containing LTR inserts, using 
primers designed to flank the cloned LTR, produced a band of approximately 740bp, 
whereas unsuccessful clones produced a band of only 310bp or alternate patterns 
(Figure 3.5A). Following restriction enzyme mapping with HindIII, positive clones 
produced bands of approximately 6470bp, 2620bp, 1930bp and 1450bp when run on 
an agarose gel. An extra band of approximately 1020bp or missing bands indicated 
unsuccessful insertion of the participant LTR (Figure 3.5B). In order to obtain positive 
clones, up to 20 colonies in three RF-cloning reactions per participant were screened. 
  
Condition Condition Set 1 Condition Set 2 Condition Set 3
DNA polymerase Phusion high fidelity Phusion high fidelity Phusion high fidelity
Denaturation time 10 seconds 30 seconds 30 seconds
Annealing time 30 seconds 50 seconds 50 seconds
Amount of insert 125ng 50ng 50ng
Amount of DpnI 10 units/reaction 10 units/reaction 20 units/reaction
DpnI digestion time 1 hour 1 hour 2 hours
Colony Positivity Rate 0% <10% 10-25%
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Figure 3.5 Screening for clones with participant LTRs incorporated into the 3’LTR position 
of the pRGH-∆U3 plasmid after RF-cloning. A) 1% agarose gel of DNA amplified from bacterial 
colonies, transformed with pRGH-∆U3 containing RF-cloned participant LTRs, which were directly 
inoculated into PCR master mixes. Screening primers were designed to flank the entire 3’LTR 
region, specifically, to the nef gene and a region downstream of the 3’U5 region within the plasmid. 
A band of approximately 740bp was expected in clones where the participant LTR had been 
inserted (same as the pRGH-WT) and a band of approximately 310bp was expected in clones with 
unsuccessful insertion (same as the pRGH-∆U3). Clones displaying both bands were also 
considered as unsuccessful insertion. Lane 1: The 1kb DNA ladder (NEB), Lane 2-7: CAP314 LTR 
RF clone transformed colonies, Lane 8-17: CAP320 LTR RF clone transformed colonies, Lane 18: 
Amplified region from the pRGH-WT plasmid, Lane 19: Amplified region from pRGH-∆U3, Lane 
20: Negative PCR control (no template DNA/bacterial colony added to reaction). B) 1% agarose 
gel of HindIII digested plasmid DNA isolated from transformed colonies displaying the correct 
banding pattern in A). Bands of approximately 6470bp, 2620bp, 1930bp and 1450bp were 
expected from clones with successful insertion of the 3’LTR (same as the pRGH-WT) and an extra 
band of approximately 1020bp (same as pRGH-∆U3) or missing bands indicated unsuccessful 
insertion of the participant LTR. Lane 1: The 1kb DNA ladder (NEB), Lane 2-5: Plasmid DNA 
isolated from colonies corresponding to lane 2, 4, 7 and 8 in A), Lane 6: Digested pRGH-WT 
plasmid DNA, Lane 7: Digested pRGH-∆U3 plasmid DNA. For both gels electrophoresis was 
performed for 40 minutes at 100V. DNA was stained with GelRedTM and the gel was visualised 
under UV light. 
 
We successfully cloned 11 of the 19 participant LTRs into the RGH-∆U3 vector (Table 
A3.1, Appendix 3). Sequencing of the 11 clones confirmed that the inserted LTR 
A)
B)
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±310bp







sequence matched the sequences amplified from the pGL4.10 panel. Pseudoviruses 
were subsequently generated from these clones. 
3.3 Cloned LTRs remain intact after infection and integration 
 
The generation of the LTR during replication is a multi-step, complex procedure which 
takes place prior to proviral integration (sections 1.6.1 and 3.2.1). Participant LTRs 
were cloned into the 3’ LTR position of the RGH plasmid with the intention of the U3 
and R regions of the participant LTR sequence being transferred to the 5’ LTR position 
upstream of the gag-eGFP cassette during replication and integration. To confirm that 
the LTR was correctly regenerated, we sequenced LTRs of two participants, CAP303 
and CAP311. To do this, genomic DNA was extracted from Jurkat E6-1 cells infected 
with LTR-pseudotyped viruses, CAP303 or CAP311. The integrated proviral 5’LTR 
sequence was amplified from this genomic DNA, and Sanger sequencing of these 
amplicons revealed that the LTR had been generated and that the sequence matched 
that of cloned participant LTRs. 
 
3.4 Construction of flow cytometry compensation controls 
 
As the read out of the latency assay was performed by flow cytometric detection of 
fluorescent proteins (section 3.6), pseudoviruses expressing each of the fluorescent 
proteins individually were generated to be used for compensation of the fluorescence 
spectral overlap (Figure A2.1 Appendix 2). To achieve this, pRGH-WT (Figure 1.5), 
was modified to express only mCherry or eGFP. 
 
To produce an mCherry-only expressing pRGH-WT clone, the eGFP gene was 
deleted by inverse PCR. To confirm deletion of the eGFP gene, DNA was amplified 
from transformed bacterial colonies, with primers designed to flank the region of the 
eGFP gene in pRGH. An amplicon of approximately 720bp was expected in clones in 
which the gene had been successfully deleted (Lanes 2, 3, 6, 7 and 10, Figure 3.6A). 
DNA isolated from bacterial colonies which produced the correct sized band was 
restriction enzyme digested with HindIII. Clones were confirmed as having the eGFP 
deletion if bands of 6470bp, 2620bp, 1450bp and 1210bp were visualised following 
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agarose gel electrophoresis (Figure 3.6B). Clones with successful deletion were 
designated as pRGH-∆eGFP. 
 
 
Figure 3.6 Screening for an mCherry only expressing pRGH plasmid. A) 1% agarose gel of 
DNA amplified from bacterial colonies, transformed with pRGH-WT plasmids after deletion of the 
eGFP gene (pRGH-∆eGFP) by inverse PCR, that were directly inoculated into PCR master mixes. 
Screening primers were designed to flank the site of the eGFP gene within the pRGH-WT plasmid, 
specifically, to the p17 and p24 regions of gag. A band of approximately 720bp was expected in 
clones where the eGFP gene had been deleted and a band of approximately 1530bp was expected 
in clones where the deletion was unsuccessful. Lane 1: The 1kb DNA ladder (NEB), Lane 2-10: 
pRGH-∆eGFP clone transformed colonies, Lane 11: Amplified region from the pRGH-WT plasmid, 
Lane 12: Negative PCR control (no template DNA/bacterial colony added to reaction). B) 1% 
agarose gel of HindIII digested plasmid DNA isolated from transformed colonies displaying the 
correct banding pattern in A). Bands of approximately 6470bp, 2620bp, 1450bp and 1210bp were 
expected in clones with successful deletion of the eGFP gene and bands of approximately 6470bp, 
2620bp, 1930bp and 1450bp indicated unsuccessful deletion. Lane 1: The 1kb DNA ladder (NEB), 
Lane 2: Plasmid DNA isolated from the bacterial colony corresponding to lane 10 in A), Lane 3: 
pRGH-WT DNA. For both gels electrophoresis was performed for 40 minutes at 100V. DNA was 
stained with GelRedTM and the gel was visualised under UV light. 
 
An eGFP-only expressing clone was created by deletion of the CMV/mCherry region 
by restriction enzyme digestion with BlpI and XhoI. A band of approximately 12470bp, 
corresponding to the remainder of the parent plasmid, was gel extracted following gel 
electrophoresis and subsequently re-ligated (Figure 3.7A). To confirm deletion, DNA 
was amplified, from transformed bacterial colonies, with primers designed to flank the 
CMV/mCherry region in pRGH. An amplicon of approximately 960bp was observed in 
clones in which the gene had been successfully deleted (Lane 3, Figure 3.7B). DNA 
isolated from bacterial colonies which produced the correct sized band was restriction 
enzyme digested with KpnI. Clones were confirmed as having the CMV/mCherry 
deleted if bands of 7300bp, 4830bp and 330bp were visualised following agarose gel 
±1530bp
±720bp












Figure 3.7 Generation and screening for an eGFP only expressing pRGH plasmid. A) 1% 
agarose gel of the pRGH-WT plasmid restriction digested with BlpI and XhoI to remove the CMV 
promoter and mCherry gene. A band of approximately 1470bp was expected containing the 
CMV/mCherry sequence, and a larger band of approximately 12470bp containing the remainder 
of the parent plasmid. The larger band (highlighted) underwent gel extraction/purification for 
subsequent ligation and transformation. B) 1% agarose gel of DNA amplified from bacterial 
colonies, transformed with re-ligated pRGH-WT plasmid after deletion of the CMV/mCherry 
sequence (pRGH-∆CMV/∆eGFP), that were directly inoculated into PCR master mixes. Screening 
primers were designed to flank the site of the CMV/mCherry region, specifically, to the nef region 
and a region downstream of the 3’U5 region within the plasmid. A band of approximately 960bp 
was expected in clones where the CMV/mCherry sequence had been deleted and a band of 
approximately 2430bp was expected in clones where the deletion was unsuccessful. Lane 1: The 
1kb DNA ladder (NEB), Lane 2-5: pRGH-∆CMV/∆mCherry clone transformed colonies, Lane 6: 
Amplified region from the pRGH-WT plasmid, Lane 12: Negative PCR control (no template 
DNA/bacterial colony added to reaction). C) 1% agarose gel of KpnI digested plasmid DNA isolated 
from transformed colonies displaying the correct banding pattern in B). Bands of approximately 
7300bp, 4830bp and 330bp were expected in clones with successful deletion of the CMV/mCherry 
sequence and bands of approximately 7300bp, 5450bp, 850bp and 330bp indicated unsuccessful 
deletion. Lane 1: The 1kb DNA ladder (NEB), Lane 2: Plasmid DNA isolated from the colony 
corresponding to lane 2 in A), Lane 3: pRGH-WT DNA. For all gels electrophoresis was performed 



















Sanger sequencing confirmed deletion of either of the reporter genes, and that clones 
maintained intact flanking regions. Pseudoviruses were generated and expression of 




Figure 3.8 Single fluorescent protein expression of flow cytometry compensation control 
pseudoviruses. Pseudocolour dot plots of Jurkat E6-1 cells infected with A) pRGH-
∆CMV/∆mCherry and B) pRGH-∆eGFP pseudoviruses. Cells were infected and analysed by flow 
cytometry 1 and 4 days post-infection in plot A and B respectively. Cells infected with pRGH-
∆eGFP were stimulated with PMA/Iono on day 3 post-infection. 
 
3.5 Optimization of RGH pseudovirus infection 
 
Pseudoviruses were initially confirmed to be infectious by viral titration in TZM-bl cells 
with titres ranging from 1398-6988 TCID50/ml. These pseudoviruses contain a Gag-
eGFP fusion protein which can be detected following infection of CD4+ T cells by flow 
cytometry. Thus during early infection, a strong eGFP signal reflects cell-free virions 
and not LTR-driven expression and is therefore not an indication of eGFP integrated 
viruses. Furthermore, it was determined by Dahabieh et al.(156), that to obtain single-
copy integrations per cell, a viral concentration/titre that yields an infection rate of 
approximately 10-20% eGFP expressing cells one day post-infection should be used. 

















one provirus was present per cell, it would not be possible to determine if proviruses 
within the same cell were displaying the same levels of transcriptional activity. 
 
Therefore, it was necessary to determine the length of time that this signal took to 
wane such that only fluorescent protein expressed from integrated provirus was 
measured. The viral titre required to yield the necessary infection rate was also 
determined for each virus. 
 
3.5.1 Determination of time to stable state of latency 
 
To determine the time taken for the initial eGFP signal to disappear and for stable 
expression of novel eGFP from integrated proviruses, Jurkat E6-1 cells were infected 
with a wild type RGH pseudovirus at volumes ranging from 50-1000µl and the eGFP 
signal was monitored over time by flow cytometry. As expected, there was an initial 
spike in eGFP at all volumes on day one post-infection. This signal gradually 
decreased over time and the signal appeared to stabilise between day four and eight 
post-infection depending on the volume (Figure 3.9). 
 
 
Figure 3.9 eGFP profile over time in Jurkat cells infected at a range of viral input volumes 
(pRGH-WT). Expression was measured to determine when incoming capsid eGFP had decayed. 
Key values represent volumes (µl) of viral supernatant added at infection. Infected cells were 
maintained under standard incubation conditions throughout the course of the sampling period and 
flow cytometric measurement of the percentage of cells expressing eGFP was performed on 1, 2, 
3, 4, 7 and 8 days post infection. 







































This experiment was repeated with the CEM.NKR CCR5+ cell line. Using a different 
pseudovirus, CAP303, at a volume determined to be optimal in the Jurkat E6-1 cell 
line (section 3.5.2), similar kinetics of decay were observed in the CEM.NKR CCR5+ 
cell line when compared to Jurkat E6-1 cells. We observed a spike of eGFP expression 
on day one post-infection which gradually decreased till day six where it began to 
stabilize (Figure 3.10). 
 
  
Figure 3.10 eGFP profile over time in CEM.NKR CCR5+ cells infected with the CAP303 
pseudovirus. Cells were infected at pseudovirus titres previously determined to be optimal for 
each pseudovirus in the Jurkat E6-1 cell line. Expression was measured to determine when 
incoming capsid eGFP had decayed. Infected cells were maintained under standard incubation 
conditions throughout the course of the sampling period and flow cytometric measurement of the 
percentage of cells expressing eGFP was performed each day post-infection. 
 
Using profiles from Jurkat E6-1 and CEM.NKR CCR5+ cells, the measurement of 
latency potential was taken at day eight post-infection for both cells lines. 
 
3.5.2 Determination of viral titre 
 
To determine the optimal viral volume to obtain 10-20% of cells expressing eGFP one 
day post-infection thus ensuring single integration events per cell, Jurkat E6-1 cells 
and CEM.NKR CCR5+ cells were infected with two volumes of viral supernatant, 50µl 
or 150µl, and 100µl or 250µl, respectively. eGFP expression was subsequently 



























measured by flow cytometry one day post-infection. Preliminary experiments 
suggested that CEM.NKR CCR5+ cells were more difficult to infect, and higher 
volumes of pseudovirus, increased spinoculation speed and smaller cell culture plates 
were used to infect these cells (Table A3.2, Appendix 3). A range of infection rates 
were obtained for each pseudovirus in both cell lines (Figure 3.11). 
 
Based on these results, a viral volume was estimated for infections such that eGFP 
expression fell between 10 and 20%, on day one post-infection. Final volumes used 




Figure 3.11 Determination of pseudovirus volume input. Percentage of GFP expressing cells 
at different viral volume for each participant LTR-pseudotyped virus. A) Jurkat E6-1 or B) CEM.NKR 
CCR5+ cells were each infected with two volumes of viral supernatant, 50 or 150µl, and 100 or 
250µl respectively and GFP expression measured 1 day post-infection by flow cytometry. 
 
3.6 Subtype C participant LTR genotype is associated with a 
range of latency potentials 
 
The effect of intra-subtype genotypic LTR variation on the frequency of latently 
infected cells early post-infection was assessed, using LTR-pseudotyped viruses 
(section 3.2). Jurkat E6-1 cells were infected with each participant pseudotyped virus 
at a volume which yielded approximately 10-20% of cells expressing eGFP on day 
A) B)





















































































one post-infection (section 3.5.2). Fluorescent protein expression (mCherry and 
eGFP) was measured by flow cytometry at eight days post-infection (section 3.5.1). 
The latency potential of each LTR was measured by determining the ratio of latently 
infected cells (mCherry only) (red) to actively infected cells (mCherry and eGFP) 
(yellow) (Figure 3.12). 
 
 
Figure 3.12 Depiction of pRGH infected cell populations detected by flow cytometric 
analysis. Pseudocolour dot plot of a pRGH infected population of Jurkat E6-1 cells. Cells within 
the upper left quadrant represent infected cells containing integrated RGH DNA with 
transcriptionally active CMV promoters but silent LTR’s (latent infection). Cells within the upper 
right quadrant represent infected cells containing integrated RGH DNA with transcriptionally active 
CMV promoters and LTR’s (active infection). Cells within the bottom left quadrant expressed 
neither fluorescent protein and were considered uninfected. 
 
In three independent experiments, the median latent:active infection ratio of 
pseudoviruses in the Jurkat E6-1 cell line was 1.97 with a range of 0.86-2.83 (Figure 
3.13). Representative flow cytometric pseudocolour dot plots are shown in Figure 
A3.3, Appendix 3. A latent:active ratio median above 1 is demonstrative of a majority 
of infected cells harbouring latent proviruses upon infection across participants. The 






















participants, while the latency potential of CAP326 differed significantly from that of 




Figure 3.13 RGH demonstrates the differences in latency observed across HIV-1 participant 
LTRs in Jurkat E6-1 cells. Jurkat E6-1 cells were infected with the participant pRGH variants. At 
7 days post-infection, cells were treated with DMSO for 24 hours and subsequently analysed by 
flow cytometry. Latency potential is expressed as the ratio of latent (mCherry only) to actively 
(mCherry and eGFP) infected cells. Error bars represent standard errors of the results of triplicate 
experiments. Participant pairs significantly different from each other are shown below (one way 
ANOVA, followed by a Tukey multiple comparison test). 
 
To confirm that silent LTRs within infected cells were transcriptionally competent, half 

































































Set Comparison p-value p-Value Summary
CAP283 vs. CAP311 0.048 *
CAP303 vs. CAP326 0.044 *
CAP311 vs. CAP326 0.003 **
CAP311 vs. CAP360 0,011 *
CAP326 vs. CAP372 0.036 *
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to induce T cell activation, thereby stimulating transcription. PMA and Iono 
cooperatively enhance the activation of cellular Protein Kinase C pathway resulting in 
T cell activation (described in section 1.9.4). Indicative of an increase of cells with 
active LTRs, a decrease in the latent:active ratio proportion decreased to below 1 in 




Figure 3.14 Latency potential in stimulated cells. Jurkat E6-1 cells were infected with the 
participant pRGH variants. At 7 days post-infection, cells were treated with PMA/Iono for 24 hours 
and subsequently analysed by flow cytometry. Latency potential is expressed as the ratio of latent 
(mCherry only) to actively (mCherry and eGFP) infected cells. Error bars represent standard errors 
of the results of triplicate experiments. 
 
The fold decrease in latency potential differed across participant LTRs, with a median 

































































Interestingly, not all proviruses in latently infected cells were reactivated as not all 
infected cells expressed eGFP post-stimulation. Furthermore, following stimulation, 
the proportion of cells expressing mCherry increased from a median of 2.5 to 9.8. 
 
3.7 LTR-associated latency potential evaluated in an alternate 
cell line 
 
To determine if the latency potential profile (latent:active ratio) (section 3.6) was a 
property of specific LTR genotype and not a property of Jurkat E6-1 infections, the 
latency assay was repeated in the CEM.NKR CCR5+ cell line. CEM.NKR CCR5+ cells 
were infected with the same panel of LTR-pseudotyped viruses (n=11) and protein 
fluorescence measured by flow cytometry. In three independent experiments, the 
median latent:active ratio was 3.15 with a range of 1.46-8.8 (Figure 3.15). 
Representative flow cytometric pseudocolour dot plots are shown in Figure A3.4, 
Appendix 3. In this cell line, a greater proportion of latently infected cells than actively 
infected cells were observed with all participant LTRs. The latency potential of CAP283 
was significantly different from that of eight other participants, while the latency 
potential of CAP311 differed significantly from that of two other participants(ANOVA, 




Figure 3.15 RGH demonstrates the differences in latency observed across HIV-1 participant 
LTRs in CEM.NKR CCR5+ cells. CEM.NKR CCR5+ cells were infected with the participant RGH 
variants. At 7 days post-infection, cells were treated with DMSO for 24 hours and subsequently 
analysed by flow cytometry. Latency potential is expressed as the ratio of latent (mCherry only) to 
actively (mCherry and eGFP) infected cells. Error bars represent standard errors of the results of 
triplicate experiments. Participant pairs significantly different from each other are shown below 

































































Set Comparison p-value p-Value Summary 
CAP283 vs. CAP303 0.028 *
CAP283 vs. CAP306 0.038 *
CAP283 vs. CAP314 0.018 *
CAP283 vs. CAP315 0.037 *
CAP283 vs. CAP320 0.023 *
CAP283 vs. CAP326 0.001 **
CAP283 vs. CAP360 0.008 **
CAP283 vs. CAP367 0.044 *
CAP311 vs. CAP326 0.007 **
CAP311 vs. CAP360 0.037 *
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We determined if the latency potential hierarchy was maintained across the CEM.NKR 
CCR5+ and Jurkat E6-1 cell lines. While there was no significant relationship when 
comparing data from all 11 participants (p = 0.18, r = 0.44) (Figure 3.16A), the 
hierarchy across participants was largely maintained when an outlier, participant 
CAP283 was excluded from the analysis (Spearman correlation test p = 0.03, r = 0.68) 
(Figure 3.16B).  CAP283 was identified as an outlier as this LTR displayed the third 
lowest latency potential in Jurkat E6-1 cells but the highest in CEM.NKR CCR5+ cells. 
This observation provides some evidence of a specific LTR sequence having an 
inherent latency potential independent of cell line. 
 
 
Figure 3.16 The association between latency potential measured in two different cell lines. 
Jurkat E6-1 and CEM.NKR CCR5+ cells were infected with participant LTR-pseudotyped RGH 
viruses and latency potential measured by flow cytometry as described in in sections 3.6 and 3.7. 
A) All participants data included B) CAP283, identified as an outlier, was excluded. A Spearman 
correlation test was performed. The dashed curves indicate the 95% confidence intervals. 






















p-value = 0.03 
r-value  = 0.68
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p-value = 0.18 
r-value  = 0.44
A)
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Similar to Jurkat E6-1 cells, after stimulation of CEM.NKR CCR5+ cells, the total 
proportion of mCherry expressing cells increased (from median of 2.8 to 7.4). 
However, unlike Jurkat E6-1 cells, the latent:active ratio increased to 4.5, indicating 
that the stimulation was not activating the latent proviruses. To determine whether this 
was due to an insufficient concentration of PMA, RGH pseudovirus-infected cells were 
treated with a range of increasing concentrations of PMA. Iono concentration 
remained constant as the initial concentration used was higher than that used for 
standard stimulation of T cells to induce viral expression(319). Increasing the PMA 
concentration 25-fold up to 100ng/ml did not reactivate these latent proviruses as an 
approximately 1.5-fold increase in the latent:active ratio compared to DMSO-treated 
cells was observed with all three PMA concentrations (Figure 3.17). Therefore, it was 
not possible to assess whether all silent infections were truly representative of latency 




Figure 3.17 The effect of PMA concentration on RGH-infected CEM.NKR CCR5+ cells. Four 
CEM.NKR CCR5+ cell cultures were each infected with either CAP315 or CAP372 LTR-
pseudotyped RGH viruses. At 7 days post-infection, each infected culture was treated with 25, 50 
or 100ng/ml of PMA and 1µM Iono or DMSO as a control for 24 hours and subsequently analysed 
by flow cytometry. Latency potential is expressed as the ratio of latent (mCherry only) to actively 
(mCherry and eGFP) infected cells. 
 
3.8 Evaluation of basal and Tat-induced LTR promoter activities 
 
We were interested to know whether LTR promoter activity influenced viral latency. 
Following HIV-1 infection, the LTR-dependent HIV-1 transcription can be divided into 
two phases. In the initial phase, which occurs immediately after integration, the LTR 
has a basal level of activity that is mediated by cellular transcription factors that interact 
with the LTR. The second phase, following the translation of HIV-1 proteins, is largely 
dependent on Tat, whereby the presence of Tat enhances gene expression. 
 
We measured basal activity by transfecting HEK293T cells with a plasmid where the 




























A2.2 Appendix 2) (plasmids provided by P Selhorst, UCT, unpublished). The Tat-
dependent activity was measured by co-transfecting the LTR-pGL4.10 clones with a 
plasmid that expressed a subtype C Tat protein (Tat-TOPO). The optimum amount of 
Tat-TOPO needed to induce promoter activity within the linear range was evaluated 
using LTRs from 11 participants. An optimum amount of 50ng of the Tat-TOPO 
plasmid per reaction was determined (Figure A3.1, Appendix 3) and used for all 
experiments. 
 
The panel of 11 participant LTRs displayed variable basal activity ranging from 0.65 
to 2.4 times BaL-LTR activity median 1.871 (Figure 3.18A and Table A3.3, Appendix 
3). Following Tat induction, significantly higher levels of LTR activity were observed 
(p-value = 0.001, Wilcoxon matched-pairs signed rank test) with a 4.8-fold mean 
increase (range 2.5-7.4). Tat-induced LTR activity had a median of 8.9 times BaL-LTR 




Figure 3.18 Basal and Tat-induced LTR promoter activity. A) Scatter plot of promoter activity 
of participant derived LTR sequences in the absence and presence of the HIV-1 Tat protein. 
HEK293 cells were transfected with each of the panel of pGL4.10 LTR clones or co-transfected 
with these clones and 50ng of the Tat-TOPO plasmid. A Renilla luciferase expressing vector was 
used to normalise transfection efficiency in all cases. LTR activity was measured by determining 
the luciferase production after the addition of luciferase at 48 h post-transfection and expressed 
as a relative response ratio to the HIV-1 subtype B Bal strain LTR luciferase expression. The 
statistical comparison was performed using the Wilcoxon matched-pairs signed rank test. The bars 
indicate the median and error bars are representative of the interquartile range. B) The association 
of basal and Tat-induced LTR promoter activity. A Spearman correlation test was performed. The 
dashed curves indicate the 95% confidence intervals. 
 























































There was one participant LTR, CAP372, which showed limited activation by Tat and 
which also had the lowest basal activity. Overall, the activity hierarchy was largely 
maintained across participant sequences in the presence and absence of Tat 
(Spearman correlation test; p-value = 0.009, r-value = 0.76) (Figure 3.18B). Of interest, 
basal transcriptional activity had a limited range, whereas this range was greatly 
expanded after Tat induction. 
 
As genotypically different LTRs had different promoter activities as well as latency 
potentials, we next wanted to determine if any relationship existed between these two 
properties. No significant correlation was observed between latency potential in Jurkat 
E6-1 cells and basal or Tat-induced LTR promoter activity (Spearman correlation 




Figure 3.19 The relationship between latency potential and LTR activity. HEK293T cells were 
transfected with A) the panel of pGL4.10 luciferase expression clones or B) co-transfected with 
the panel of pGL4.10 luciferase expression clones and 50ng of the Tat-TOPO plasmid. A Renilla 
luciferase expressing vector was used to normalize transfection efficiency. LTR activity was 
measured by luciferase expression after the addition of luciferin at 48 h post-transfection and was 
expressed as a response ratio relative to the HIV-1 BaL strain LTR luciferase expression. Latency 
potential is expressed as the latent:active ratio of DMSO treated samples as in Figure 3.13. The 
dashed curves indicate the 95% confidence intervals. 
 
3.9 Influence of LTR genotype on latency potential 
 
It has been demonstrated that a minor genotypic deviation from the consensus in 
domains of the LTR associated with binding of regulatory cellular factors was sufficient 












































to alter latency establishment(101). To investigate the underlying factors contributing 
to the differences in LTR-dependent latency, we investigated if there were genotypic 
features associated with LTR-dependent latency. 
 
In order to characterise and identify the differences from the consensus C sequence 
within each participant-specific LTR, (HXB2 position 1-532) a Highlighter plot 
(www.hiv.lanl.gov) was generated. Participant LTRs largely resembled the subtype C 
consensus sequence with differences away from consensus distributed across the 
length of each LTR (Figure 3.20). CAP360, CAP303 and CAP320 each harboured a 
15-21bp insertion between HXB2 site 326-327, with CAP320, harbouring an additional 
NF-κB-like motif inserted in this site, upstream of the canonical three sites in the 
enhancer region. One participant LTR, CAP372, had a single base pair difference from 
consensus in the AP-1 binding site within the enhancer region.
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Figure 3.20 CAPRISA 004 LTR genotypic differences away from a consensus C LTR. Highlighter (www.HIV.LANL.gov) plot of the U3 and R regions of the panel 
of participant LTR sequences. Tic marks represent nucleotide substitutions as compared to the top-most Subtype C Consensus LTR sequence. Sequences are listed 
from top to bottom in order of least to most distant from consensus. Sites of well-characterised cis-regulatory elements, where published consensus binding sites could 
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Additionally, we measured the pairwise DNA distance of each participant LTR to a 
consensus C LTR (HXB2 position 1-532). There was higher overall DNA distance from 
LTR consensus C (median 0.056; range 0.039-0.094), compared to the 19 domains 
associated with regulation (median 0.047; range 0.026-0.087) (Figure 3.21). One 
participant LTR, CAP372, was highly divergent from the consensus sequence. 
 
 
Figure 3.21 Scatter plot of pairwise DNA distances between a consensus C LTR sequence, and 
each of the selected panel of pGL4.10 cloned participant LTR sequences. Distances were 
calculated across the entire sequence and within functional sites. The number of base substitutions 
per site between sequences are shown. Analyses were conducted using the Maximum Composite 
Likelihood model(318). A total of 532 positions were analysed. The bars indicate the mean and error 
bars represent the standard deviation. 
 
Interestingly, the average number of mutations per functional site was higher in the 
modulatory region than both the enhancer and core promoter regions. The enhancer 
region was the most highly conserved with an average DNA distance of 0.021 per 

































Figure 3.22 CAPRISA 004 LTR DNA distance from a consensus C sequence within each 
functional site. The bars indicate the mean and error bars represent the standard deviation. 
 
We next wanted to determine if any association existed between the average DNA 
distance per functional site from a consensus C LTR and participant-specific latency 
potential, given the variability within the LTR. No significant correlation was observed, 

























































































Figure 3.23 The association between CAPRISA 004 LTR latency potential and DNA distance 
from a consensus C LTR sequence within functional sites. Latency potential is expressed as the 
latent:active ratio of DMSO treated samples as in Figure 3.12. The dashed curves indicate the 95% 
confidence intervals. 
  

































r-value  = -0.25
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Chapter 4: Discussion 
 
HIV-1 latency remains the greatest barrier to eradication of the virus from an infected 
individual. Latency allows viral DNA to persist in the presence of all current therapeutic 
strategies, and for re-emergence of viremia after treatment interruption. Transcriptional 
silencing of the HIV-1 promoter element, the LTR, plays an important role in the 
occurrence of viral latency(79, 147, 320). However, the role of viral factors in latency 
remains poorly understood. In this study, we investigated the role of LTR genotype on 
HIV-1 latency establishment. Using LTRs from acutely infected South African women, 
representative of the subtype C epidemic, we implemented an in vitro model to measure 
the proportion of latently infected cells shortly after infection (latency potential) and 
evaluate how this potential relates to promoter strength. We found that latency potential 
varied across subtype C LTRs and was not influenced by promoter activity as measured 
by transcription in the presence and absence of Tat. Furthermore, we found that viruses 
that were divergent from the most common sequence (subtype C consensus) did not have 
significantly different latency potentials. To our knowledge, this is the first study to 
characterize the influence of inter-participant, intra-subtype C genotypic diversity on HIV-
1 viral latency. 
 
We used a dual reporter latency model developed by Dahabieh et al., (2013) to measure 
latency(156). This model enables identification of three populations of cells, including, 
uninfected cells, cells harbouring latent virus and those with actively replicating viruses. 
This is achieved using two independent reporter genes, mCherry (integration marker) and 
eGFP (viral expression marker) that are under the control of a constitutive CMV promoter 
and the HIV-1 LTR promoter respectively. This dual reporter system has an advantage 
over other single reporter based systems, such as those developed by, Jordan et al.(240), 
and Burke et al.(255), in that it provides a positive marker for latent infection and negates 
the need for selection of only latently infected cells. 
 
We show that latency potential varied across LTR sequences derived from 11 subtype C 
acutely HIV-1 infected women, with significant differences across multiple individuals. 
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However, the range of intra-subtype C latency potential was smaller than that observed 
in LTRs from different subtypes(156), supporting the hypothesis that the degree of 
variation of the LTR plays an important role in influencing latency potential. 
 
Latency establishment is a phenomenon reliant on a variety of molecular mechanisms, 
acting in synergy to induce the latent state(79, 147, 320). Some of these mechanisms do 
not directly target the LTR. In the current model, the majority of cellular conditions were 
assumed to be homogenous, and in Jurkat E6-1 cells, the latency potential hierarchy 
within the 11 participant LTRs was maintained across replicate experiments. This 
demonstrates that there is an inherent genotype-dependent property of HIV-1 LTRs that 
influences the latency potential of a specific virus. However, although conditions in tissue 
culture are assumed to be uniform, it was not possible to completely control for all 
intracellular factors such that the LTR genotype of the infecting virus was the only variable 
factor in the system. This may therefore account for variations across samples. 
 
Consistent with findings by Dahabieh et al.(156), we observed that, days after infection 
of the Jurkat E6-1 cell line, the majority of infected cells harboured transcriptionally silent 
proviral DNA. This suggests that the virus has the capacity to extensively establish 
latency early post-infection. However, it is important to note that a range of other in vivo 
factors may influence which cells become latently infected. Therefore, this model provides 
the advantage of investigation of viral factors in isolation. Given that the RGH model only 
measures the proportion of infected cells in which latency is established within a few days 
of infection, and that mechanisms of latency establishment are unknown, the effect of 
longer culture on the proportion of latently infected cells cannot be speculated. 
 
We were able to detect latently infected cells in our cultures eight days post-infection. 
However, it is possible that latency was established earlier but could not be measured 
due to masking by residual eGFP. Additionally, the cell lines utilised for infections were 
actively proliferating and not resting populations. Although latency is thought to be 
established when actively infected CD4+ T cells transition to a resting memory state in 
vivo, detection of latent provirus in our study cells disputes this theory, and supports the 
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multiple studies that report that actively infected CD4+ T cells can harbour 
transcriptionally silent HIV-1 provirus(146, 147, 151, 157). 
 
Post-stimulation, the proportion of latently infected cells decreased in the Jurkat E6-1 cell 
line. This confirms that latency was successfully established in a subset of cells and these 
viruses were inducible via T cell activation. If all infected cells were capable of actively 
transcribing mCherry and eGFP, cells expressing both proteins would be expected to be 
present post-stimulation. However, since mCherry-only expressing cells remained, we 
hypothesised that (i) PMA/Iono stimulation was insufficient to activate all silent LTRs, (ii) 
the mechanism of silencing was not directly related to transcription/the LTR, or (iii) some 
cells were infected with a provirus with a non-functional eGFP cassette. Unlike Jurkat E6-
1 cells, stimulation of the CEM.NKR CCR5+ cells did not decrease the latent:active ratio 
even at higher concentrations of PMA. These cells were either resistant to PMA 
activation, or the cells were already partially activated, and PMA did not increase the 
activation threshold sufficiently to reactivate the silent LTRs. Alternatively, latency could 
have been established by an alternate mechanism to that in Jurkat E6-1 cells and was 
not reversible by effects induced by PMA/Iono in this cell line. To our knowledge, only 
one study has investigated the effect of PMA/Iono on CEM.NKR CCR5+ cells and it was 
shown that it induced internalization of the CXCR4 co-receptor, however this is not likely 
to impact the activation state of the cell or ability to reverse latency(321). 
 
Although the CMV promoter is considered a strong promoter, it has previously been 
demonstrated, albeit in myeloid cell lineages, that the promoter can be silenced via 
histone modifications(322, 323). It has also been shown that the CMV promoter is 
sensitive to T cell activation, with increased transcription of the immediate early genes 
under the control of this promoter observed upon PMA treatment(324, 325). Interestingly, 
we observed an overall increase in the proportion of infected cells (mCherry expressing), 
in both cell lines, following PMA/Iono stimulation. This observation suggests that not all 
infected cells expressed mCherry constitutively. Furthermore, this indicates that 
PMA/Iono is capable of activating the CMV promoter. It is therefore possible that the 
model may underestimate the number of HIV-1 infected cells and, it would be pertinent 
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to replace the CMV promoter with an alternative promoter such as the EF1a, ACTB or 
PGK promoters that have been observed to be more stable in a range of cell lines(326). 
 
It has been demonstrated that the replicative capacity and fitness of a virus is influenced 
by subtype-level genotypic variation of its LTR(77, 78). This was proven to be due to the 
presence of specific motifs e.g. additional NF-κB site in subtype C or an additional TATAA 
box sequence in subtype E. Conservation of a binding sequence for AP-1, present in 
some HIV-1 subtype LTRs but not in others, has been shown to promote the ability of the 
different viruses to establish latency(101). This AP-1 site was highly conserved across 
our participant LTRs, with the exception of a single difference away from consensus in 
one participant. Interestingly, this sequence displayed one of the highest latency 
potentials in our panel. It is possible that this single site does not act independently on 
latency establishment and that there is an interplay of cis-regulatory factors during this 
process. Furthermore, no correlation was observed overall between latency potential and 
the frequency of nucleotide differences in LTR functional sites or overall DNA distance 
from the consensus C sequence. It is likely that latency is influenced by a range of 
complex mechanisms and differences from the consensus may have a positive, negative 
or negligible effect on viral latency. Further studies are needed to evaluate this. 
 
We hypothesized that highly transcriptionally active LTRs would be more resistant to 
transcriptional silencing and would therefore be less prone to viral latency. However, no 
relationship between latency potential and either basal or Tat-induced promoter activity 
was observed. This finding suggests that Tat interaction may not directly influence the 
ability of the virus to establish latency however, this conclusion cannot be drawn due to 
the small sample size of our study. Assuming that tat and the TAR loop co-evolve to allow 
optimal interaction, we attempted to reduce diversity at this level by using a subtype C 
Tat-expressing plasmid with the tat sequence isolated from a CAPRISA 002 patient. 
However, this tat sequence was not matched to any of the participant LTRs, and it is 
possible that utilising a participant-matched Tat may more accurately represent in vivo 
conditions. Alternatively, using the subtype B Tat expressed in the RGH model may allow 
for better comparison between activity and latency potential. 
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A general limitation of our study was the low number of participant LTRs in our panel, 
resulting in weak statistical power particularly with correlation analyses. The limited 
number was primarily due to difficulties cloning the LTRs into the RGH vector. Therefore, 
future studies should aim to further optimize cloning of LTRs into the RGH vector, in order 
to develop a high-throughput method of generating a large panel of participant-specific 
LTR clones. This could potentially be achieved by replacing the RF-cloning procedure 
with a standard restriction cloning via the use of a shuttle vector system. 
 
In addition, many studies on latency have been performed with on-therapy patients. While 
the composition of the reservoir is still being characterised, studies indicate that viruses 
in the reservoir resemble those from chronic infection(327). Whereas, LTRs in this study 
were isolated from acutely infected patients. Therefore, this model can be made more in 
vivo relevant by investigating chronic LTRs, longer term culture of RGH pseudovirus 
infected samples and the infection of primary cells isolated from donors. 
 
In conclusion, our study provides evidence to suggest that subtype C viruses, can directly 
and rapidly establish latency within a large proportion of non-resting CD4+ T cells. Inter-
participant genotypic variation within the LTR of an infecting virus was shown to have a 
direct role on the proportion of viruses which established latency, i.e. each LTR had an 
inherent latency potential. The precise mechanisms of latency remain largely unknown. 
However, since latency potential was independent of basal and Tat-induced LTR activity, 
other factors such as regulatory element interaction and the efficiency of recruitment of 
molecules responsible for establishing latency, such as histone modifiers, may play a 
role. Identification of these cellular factors, and the early latently infected cells themselves 
in infected patients, could provide useful insights into targets for treatment and prevention 





Appendix 1. Reagents and buffers 
 
The materials described hereafter and the methods in which they can be used are 
described in Molecular Cloning: A Laboratory Manual(328). 
 
Tris/Acetate/EDTA (TAE) buffer: (10x 1 Liter) (stored at room temperature) 
 
1. Dissolve 48.4 g Tris and 11.42mL glacial acetic acid in 900 ml distilled water 
2. Add 3.722g of Na2EDTA (pH 8.0) 
3. Adjust volume to 1 Liter 
 
Carbenicillin: (100 mg/mL) (stored at -20˚C) 
 
1. Weigh 1000 mg carbenicilin disodium salt (98-100% anhydrous) 
2. Dissolve in 10 mL distilled, de-ionized H2O in a 15 mL tube 
3. Vortex to ensure that all the salt is dissolved 
4. Using a syringe, pass the solution through a 0.22 μm filter into a fresh, sterile tube 
 
Luria-Bertani Broth: (stored at room temperature) 
 
1. Add the following to 800 mL H2O:  
10g Bacto-tryptone 
5g yeast extract 
10g NaCl 
2. Adjust pH to 7.5 with NaOH or HCl 
3. Adjust the volume to 1 L with dH2O 
4. Sterilize by autoclaving at 121C for 15 minutes 
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Luria-Bertani Agar: (stored at 4˚C) 
 
1. Add the following to 800ml H2O: 
10g Bacto-tryptone 
5g yeast extract 
10g NaCl 
2. Adjust pH to 7.5 with NaOH or HCl 
3. Add 15g agar and dissolve by heating in the microwave 
4. Adjust the volume to 1l with dH2O 
5. Sterilize by autoclaving at 121˚C for 15 minutes 
 
Preparation of agar plates: 
 
1. Prepare LB Agar as above and allow to cool 
2. Add 1μl carbenicilin (100 mg/ml as above) per ml of agar using sterile technique 
3. Add to sterile petri dishes until the height of the liquid ~1cm thick 
4. Allow to set before storing the plate with the lid facing down 
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Appendix 2. Supplementary methods 
 
 
Figure A2.1 Emission spectra of eGFP and mCherry fluorescent proteins excited at 488nm. The 515/20 and 610/20 bandpass filters for detection of 
eGFP and mCherry respectively, are indicated. Upon excitation at 488nm, the eGFP emission spectra spilt over into the 610/20 filter.
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Table A2.1 List of all PCR primers used for this study. Reverse primer HXB2 positions are indicated in red. 
 
 
C = Cloning 
PA = PCR Amplification 
S = Sequencing 
CPS  = Colony PCR Screening
Primer Name
Sequencing 
Direction Primer Sequence Length (mer) HXB2 position Purpose
^eGFP-pRGH-FP Forward 5’-AGC CAA AAT TAC CCT ATA GTG CAG AAC CTC-3’ 30 1174→1203 C
^eGFP-pRGH-InvPCR(R) Reverse 5’-GAC CTG GCT GTT GTT TCC TGT GTC AC-3’ 26 1148←1173 C
cLTR_F Forward 5’-AAC TAC ACA CCG GGA CCA GGG-3’ 21 87→107 PA/S
gagB-R Reverse 5’-CTC CCT GAC ATG CTG TCA TCA T-3’ 22 1825←1846 CPS/S
gagD-F Forward 5'-TCT CTA GCA GTG GCG CCC G-3' 19 626→644 S
gagD-R Reverse 5'-AAT TCC TCC TAT CAT TTT TGG-3' 21 2382←2402 S
GF40 Forward 5’-GAC ACC AAG GAA GCC TTA GA-3’ 20 1075→1094 CPS/S
GF80 Forward 5'-AGA GAA CCA AGG GGA AGT GA-3' 20 1477→1493 S
Nef F Forward 5′-CCT AGA AGA ATA AGA CAG GGC TT-3′ 22 8754→8775 CPS
pRGH Colony RP Reverse 5’-TCA TGT TTG ACA GCT TAT CAT CGC C-3’ 25 N/A CPS/S
pRGH_LTR_F Forward 5’-CCA TCT CGA GGT GCC TTT AAG ACC AAT GAC-3’ 30 9006→9035 PA/CPS/S
pRGH_LTR_R Reverse 5’-TAC CAA CAG TAC CGG ATT GC-3’ 20 N/A PA









Figure A2.3 Schematic depiction of the 3’LTR-∆U3 RGH plasmid. Plasmid used for generation 
of LTR-pseudotyped viruses. pRGH is derived from pLAI full length replication competent, 
infectious HIV-1 subtype B LAI molecular clone. An eGFP gene has been inserted in-frame 
between the matrix and capsid regions of the gag gene. The env open reading frame was disrupted 
by a single base pair deletion at position 7136 resulting in a frameshift. The nef gene has been 
partially deleted and been replaced with a CMVIE driven mCherry gene construct. The U3 region 















































Appendix 3. Supplementary data 
 
Table A3.1 CAPRISA 004 participants selected for inclusion in the LTR panel 
 
* PID = Participant Identification Number 
** Weeks post-infection is estimated based on last negative and first positive HIV-
1 test result. 
*** Pairwise DNA distance of each participant LTR sequence to a global subtype 
C LTR (described in section 3.9.1). 
 
Table A3.2 eGFP expression in CEM.NKR CCR5+ cells infected with the CAP283 and CAP306 
pseudoviruses one day post-infection. Cells were infected at pseudovirus volumes previously 
determined to be optimal for each pseudovirus in the Jurkat E6-1 cell line. 
 














CAP283 7 2007 0.073 12900 403 Yes
CAP292 5 2008 0.061 458000 510 No
CAP303 4 2008 0.043 344000 469 Yes
CAP306 8 2008 0.063 141000 853 Yes
CAP308 9 2008 0.072 37100 473 No
CAP311 6 2008 0.051 18600 346 Yes
CAP314 12 2008 0.050 166000 358 Yes
CAP315 3 2008 0.058 108000 519 Yes
CAP317 7 2008 0.078 351000 377 No
CAP320 5 2008 0.058 37500 851 Yes
CAP326 3 2008 0.056 31500 470 Yes
CAP327 3 2008 0.057 91600 689 No
CAP343 7 2009 0.056 130000 332 No
CAP345 6 2009 0.081 130000 379 No
CAP355 3 2009 0.048 19700 466 No
CAP360 3 2009 0.051 80600 450 Yes
CAP367 3 2009 0.039 3360000 228 Yes
CAP368 4 2009 0.084 1180 841 No
CAP372 3 2009 0.094 107000 424 Yes
PID*







Figure A3.1 Determination of Tat-TOPO plasmid concentration input. HEK293T cells were 
co-transfected with each pGL4.10 participant LTR plasmid and the Tat-TOPO at a range of 
concentrations. A Renilla luciferase expressing vector was used to normalize transfection 
efficiency in all cases. LTR activity was measured by luciferase expression after the addition of 
luciferin at 48 h post-transfection, and is expressed as a response ratio relative to the HIV-1 Bal 
strain LTR luciferase expression. 
 
Table A3.3 Volumes of each participant pseudovirus used for infections in the latency 
potential assays.  
 






























PID* Volume of PSV** (µl)
Percentage eGFP one 
day post-infection (%) Volume of PSV** (µl) 
Percentage eGFP one 
day post-infection (%).
CAP283 50 15.2 100 19.5
CAP303 21 8.5 41 16.8
CAP306 50 12.2 150 17.4
CAP311 15 7.2 54 15.3
CAP314 15 6.9 45 13.6
CAP315 18 11.3 25 8.76
CAP320 25 9.7 45 12,0
CAP326 12 6,0 40 10.7
CAP360 24 9.5 52 11.5
CAP367 32 11.7 230 26.5
CAP372 50 12.0 90 16.8
Jurkat E6-1 CEM.NKR CCR5+
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* PID = Participant Identification Number 
** PSV = Pseudovirus 
 
Figure A3.2 Pseudocolour dot plots of populations of Jurkat E6-1 cells infected with the 
CAP283 and CAP372 RGH pseudoviruses. Jurkat E6-1 cells were infected with each participant 
RGH variants. At 7 days post-infection, cells were treated with either DMSO or PMA/Iono for 24 


















Figure A3.3 Pseudocolour dot plots of populations of CEM.NKR CCR5+ cells infected with 
the CAP311 and CAP326 RGH pseudoviruses. Jurkat E6-1 cells were infected with each 
participant RGH variants. At 7 days post-infection, cells were treated with either DMSO or 

















Table A3.4 Basal and Tat-induced LTR activity relative to BaL of each participant LTR 
 
* PID = Participant Identification Number 
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